

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05964 A1

- (51) International Patent Classification: C12N 15/12, 15/11, C12Q 1/68, C07K 14/475, 16/18, A61K 38/18, G01N 33/68
Street, Mount Waverley, VIC 3149 (AU), NG, Kong, Wah [AU/AU]; 62 Monash Avenue, Balwyn, VIC 3103 (AU).
- (21) International Application Number: PCT/AU00/00864 (74) Agent: GRIFFITH HACK: 509 St Kilda Road, Melbourne, VIC 3004 (AU).
- (22) International Filing Date: 19 July 2000 (19.07.2000) (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 19 July 1999 (19.07.1999) AU (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 41 Victoria Parade, Fitzroy, VIC 3065 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ZHOU, Hong [AU/AU]; 69/50 King William Street, Fitzroy, VIC 3065 (AU). KARTSOGLANNIS, Vassiliki [AU/AU]; 5 Almond Court, Thomastown, VIC 3074 (AU). HU, Yunshan [AU/AU]; 1/19 Boordex Avenue, Blackburn, VIC 3130 (AU). GILLESPIE, Matthew, Todd [AU/AU]; 7 Baily

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITOR OF OSTEOCLAST PRECURSOR FORMATION

(57) Abstract: This invention relates to a polypeptide factor which is able to inhibit the formation of osteoclasts. In particular, the invention relates to a factor which inhibits the differentiation of haematopoietic precursor cells into mononucleate osteoclast precursors. In a preferred form of the invention, the factor is a type (II) membrane polypeptide expressed on the osteoblast cell surface, which we have designated osteoclast inhibitory lectin (OCIL). Nucleic acids encoding the polypeptide factor, polypeptides, and antibodies to the polypeptide are disclosed and claimed. The factor is useful in the treatment of conditions associated with abnormalities of bone resorption.

WO 01/05964 A1

- 1 -

INHIBITOR OF OSTEOCLAST PRECURSOR FORMATION

This invention relates to a polypeptide factor which is able to inhibit the formation of osteoclasts. In particular, the invention relates to a factor which inhibits the differentiation of haematopoietic precursor cells into mononucleate osteoclast precursors. In a preferred form of the invention, the factor is a type II membrane polypeptide expressed on the osteoblast cell surface, which we have designated osteoclast inhibitory lectin (OCIL).

BACKGROUND OF THE INVENTION

In normal adults, the processes of bone formation and resorption are balanced in order to maintain a normal healthy bone mass. With the onset of the menopause in females and with ageing in both sexes, the rate of bone resorption exceeds that of bone formation, resulting in net bone loss, and ultimately in osteoporosis.

Osteoblasts are the bone cells responsible for bone formation, while osteoclasts are responsible for resorption of bone. Our understanding of the factors that regulate the formation and function of osteoclasts has been greatly enhanced by laboratory methods that have enabled us to isolate and grow these cells in culture. It is now well established that the development of active osteoclasts in vitro requires intimate contact between osteoblastic stromal cells and precursors of osteoclasts which are derived from haematopoietic cells belonging to the monocyte/macrophage lineage (Takahashi *et al*, 1988). This process is influenced by a variety of factors, including 1,25-dihydroxyvitamin D₃, parathyroid hormone, prostaglandin E₂, and interleukins 6, 11 and 17, all of which enhance osteoclast formation. In contrast, cytokines such as interleukins 4, 10, 13 and 18 are inhibitory (Suda *et al*, 1995; Martin and Udagawa, 1998).

All factors which stimulate osteoclast formation

- 2 -

act directly on the osteoblast population and not on the osteoclast precursors, leading to the proposal that osteoblasts or stromal cells express a membrane-associated peptide that regulates the formation of functional

5 multinucleate osteoclasts. A factor, termed "Osteoclast Differentiation Factor" (ODF), that fulfils the functions of such a putative membrane-associated peptide has recently been cloned. ODF encodes a 316 amino acid type II transmembrane protein, and is a member of the TNF ligand

10 family (Yasuda et al, 1998). Recombinant protein corresponding to the extracellular domain of ODF stimulates the formation of active, bone-resorbing osteoclasts from haematopoietic cells within the spleen, even in the absence of stromal cells. A peptide identical to ODF has also been

15 cloned from T cells, and designated Tumour Necrosis Factor-related activation-induced cytokine (TRANCE; Wong et al, 1997), or receptor activator of NF- κ B ligand (RANKL; Anderson et al, 1997). When released by T cells following activation of the T cell receptor, it mediates the

20 interaction of T cells and dendritic cells, resulting in stimulation as well as increased survival of the naive T cells. RANK, another member of the TNF-receptor family, has been identified on dendritic cells, and acts as the receptor for TRANCE/RANKL (Wong et al, 1997; Anderson et

25 al, 1997).

Osteoprotegerin (OPG) is a soluble factor that belongs to the Tumour Necrosis Factor (TNF) receptor family. This factor is also known as Osteoclastogenesis Inhibitory Factor (OCIF). It has been shown to bind to

30 TRANCE/RANKL/ODF, resulting in the inhibition of formation of functional multinucleate osteoclasts *in vitro*. OPG is a 401 amino acid polypeptide. Overexpression of OPG in transgenic mice results in severe osteopetrosis, with a loss of bone marrow cavities and profound depletion of

35 osteoclasts. The same effects were observed upon administration of OPG to normal mice. Furthermore, OPG blocked ovariectomy-associated bone loss in rat. OPG mRNA

- 3 -

transcripts have been identified within bone and cartilage, vascular structures, midgut and kidney, and in several osteoblast cell lines. Current data suggest that OPG blocks the terminal stages of osteoclast differentiation, but not the formation of mononuclear osteoclast precursors (Simonet *et al*, 1997; Tsuda *et al*, 1997). The nomenclature adopted throughout this specification is RANKL, OPG and RANK, in accordance with that proposed by Suda *et al.*, (1999).

The interaction between RANKL and OPG in the formation of osteoclasts is illustrated in Figure 1. Osteoclasts are derived from haematopoietic stem cells that differentiate along the monocyte/macrophage lineage. Mononuclear precursors of osteoclasts are required to come into direct or close contact with osteoblasts to be rendered capable of differentiating into mature, functional, multinucleate osteoclasts. Osteoblasts express RANKL, a membrane-bound protein that stimulates the differentiation and formation of multinucleate osteoclasts from mononuclear precursors when it binds to its receptor, RANK. RANKL expression is stimulated by bone-resorbing factors such as PTH, PGE₂, 1,25-dihydroxyvitamin D₃ and interleukins 6 and 11. The action of RANKL is antagonised by Osteoprotegerin, a soluble factor secreted by osteoblastic stromal cells. It binds to RANKL to inhibit the formation of differentiated multinucleate osteoclasts, but does not prevent the formation of mononuclear osteoclast precursors.

It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.

We have now identified a polypeptide factor which is able to inhibit formation of mononuclear osteoclast precursors from haematopoietic stem cells, and which is expressed at least on the cell membranes of osteoblasts.

- 4 -

It appears that when the molecule is expressed on the osteoblast cell membrane it is not secreted. Preventing expression of the factor results in increased formation of mononuclear precursors of osteoclasts.

5

SUMMARY OF THE INVENTION

In a first aspect, the invention provides a nucleic acid molecule which comprises a sequence encoding a protein which

10 a) is expressed at least on osteoblasts, and inhibits osteoclast differentiation from haematopoietic cell precursors,

or which hybridises to said nucleic acid molecule under stringent conditions.

15 Suitable stringent conditions are well known in the art. See the well known textbook by Sambrook et al (1989), and Example 2 herein.

The nucleic acid may be cDNA, genomic DNA or messenger RNA. Preferably the nucleic acid molecule is a
20 cDNA. More preferably the cDNA comprises a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11, SEQ ID NO: 33, SEQ ID NO: 36, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.

25 Preferably the protein inhibits differentiation of haematopoietic cells to osteoclast cells. In a particularly preferred embodiment, the nucleic acid molecule of the invention comprises a 110 base pair sequence as set out in SEQ ID NO: 2.

30 This aspect of the invention also encompasses anti-sense sequences directed against the nucleic acid molecule defined above, and particularly encompasses an anti-sense sequence directed against SEQ ID NO: 10. Preferably the anti-sense sequence is SEQ ID NO: 24 or SEQ
35 ID NO: 25.

In a second aspect, the invention provides a polypeptide encoded by the nucleic acid molecule of the

- 5 -

invention. Preferably the polypeptide is encoded by the human cDNA sequence. More preferably the polypeptide comprises an amino acid sequence encoded by SEQ ID NO: 20.

In a third aspect, the invention provides an
5 antibody directed against a polypeptide of the invention. Preferably the antibody is directed against an epitope present in a sequence selected from the group consisting of

H-Cys-Met-Ala-Gln-Glu-Ala-Gln-Leu-Ala-Arg-Phe-Asp-Asn-Gln-
10 Asp-Glu-Leu-Asn-Phe-OH (SEQ ID NO: 26),

H-Cys-Val-Thr-Lys-Ala-Ser-Leu-Pro-Met-Leu-Ser-Pro-Thr- Gly-
Ser-Pro-Gln-Glu-NH₂ (SEQ ID NO: 48), and

15 H-Cys-Val-Gln-Lys-Pro-Glu-Glu-Gly-asn-Gly-Pro-Leu-Gly-Thr-
Gly-Asp-NH₂ (SEQ ID NO: 49).

The antibody may be polyclonal or monoclonal, but is preferably monoclonal. Suitable methods for generating
20 either polyclonal or monoclonal antibodies are very well known in the art. It will be clearly understood that the invention encompasses biologically-active fragments and analogues of such antibodies, including but not limited to ScFv fragments, trimeric antibodies, humanised antibodies
25 and the like. Again, methods for producing such active fragments and analogues are well known in the art. See for example PCT/AU93/00491 and PCT/AU97/00212 and references cited therein.

In a fourth aspect, the invention provides a
30 composition comprising a polypeptide or an antibody of the invention, together with a pharmaceutically-acceptable carrier.

Methods and pharmaceutical carriers for
preparation of pharmaceutical compositions are well known
35 in the art, for example as set out in textbooks such as Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton, Pennsylvania, USA.

- 6 -

In a fifth aspect, the invention provides a method of treatment of a condition characterised by abnormal bone resorption, comprising the step of administering an effective amount of a modulator of
5 expression or function of the polypeptide of the invention.

Where the condition involves excessive bone resorption, the method will comprise administration of the polypeptide of the invention or the nucleic acid encoding this polypeptide, or a biologically-active fragment or
10 analogue thereof. Such conditions include, but are not limited to, osteoporosis, primary hyperparathyroidism, Paget's disease, rheumatoid arthritis, renal osteodystrophy, humoral hypercalcaemia of malignancy, and conditions where cancer has metastasised to bone.

15 Conditions characterised by deficient bone resorption include osteopetrosis. Antibodies directed against the polypeptide of the invention or anti-sense oligonucleotides directed against the nucleic acid of the invention may be used to inhibit the function of the
20 polypeptide and thus to increase bone resorption.

It is also contemplated that the polypeptide of the invention may be used to promote healing of bone fractures, particularly in individuals where fracture healing is delayed or deficient. These include individuals
25 suffering from osteoporosis or diabetes mellitus.

Factors which influence bone resorption, such as parathyroid hormone-related protein and RANKL, affect breast development by altering apoptosis of cells. The OCIL factor of the invention also appears to alter apoptosis of
30 cells, and may therefore participate in breast and lymph node development, similarly to other agents which modulate bone resorption.

Thus in a sixth aspect, the invention provides a method of modulating breast and lymph node development,
35 comprising the step of administering an effective amount of a modulator of expression or function of the polypeptide of the invention to a subject in need of such treatment.

- 7 -

In a seventhth aspect, the invention provides a diagnostic kit, comprising a reagent selected from the group consisting of a nucleic acid of the invention or a fragment thereof capable of hybridising to a nucleic acid of the invention; an anti-sense nucleic acid of the invention; a polypeptide of the invention, and an antibody of the invention. For example, diagnostic kits for use in methods such as polymerase chain reaction, fluorescent *in situ* hybridisation, immunoassay, and the like are contemplated. Where appropriate, the molecule of the invention which is used may be labelled with a detectable marker, such as a radioactive, fluorescent, chemiluminescent or enzymic marker. Such diagnostic kits are useful for detection of abnormalities in the structure, expression or control of the factor of the invention, which may lead to increased bone resorption and concomitant pathological manifestations. They are also useful for screening of candidate drugs to assess their ability to modulate expression or function of the polypeptide of the invention.

For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 summarises the factors and mechanisms involved in control of osteoclast differentiation and development, as understood before the date of the present invention.

Figure 2 shows detection by Northern blotting of a 780 base pair mRNA species using rOCIL323 (SEQ. ID NO: 2) as a probe in a variety of rat clonal osteoblast-like cell lines, which were either untreated or subjected to treatment with 10^{-6} M retinoic acid for 24 hours.

Figure 3 shows the results of Northern blot analysis of rat clonal osteoblast-like cell lines treated

- 8 -

with 10^{-6} M retinoic acid, using rOCIL402 (SEQ. ID NO: 4),
a 402 base pair fragment obtained by screening of a rat ROS
17/2.8 cDNA library using the polymerase chain reaction.
Similar results were obtained using rOCIL323 fragment as a
5 probe.

Figure 4 shows the comparison of rOCIL323 and
rOCIL402 probes in Northern blotting of mRNA from 1,25-
dihydroxyvitamin D_3 -treated rat UMR 106-06 cells. The
results showed that both fragments detected the same
10 species of mRNA.

Figure 5 shows the results of Northern blot
analysis of UMR 201 mRNA using mOCIL 2kb (SEQ ID NO: 10),
showing that this probe detected the same 780 bp species as
rOCIL323 and rOCIL402.

15 Figure 6 shows the intron-exon structures of the
mOCIL gene (SEQ ID NO: 10) and of the mOCILrP1 gene ((SEQ
ID NO: 11).

Figure 7 summarises the homology between mOCIL,
mOCILrP1 and mOCILrP2.

20 Figure 8 shows the deduced protein sequences
corresponding to mOCIL (Figure 8a), mOCILrP1 (Figure 8b),
and mOCILrP2 (Figure 8c), illustrating the domain structure
of each protein.

Figure 9 shows a comparison between the deduced
25 protein sequences of mOCIL, mOCILrP1, and mOCILrP2, as
generated using the program Clustal W.

Figure 10 shows the results of treatment of
cocultures of primary mouse calvarial osteoblasts and mouse
bone marrow cells with an anti-sense oligonucleotide, 323
30 A/S (SEQ ID NO: 22) and 402 A/S (SEQ ID NO: 23), directed
against the C-type lectin region of OCIL, antisense
oligonucleotide, 474 A/S (SEQ ID NO: 25), which was
directed against the sequence in the open reading frame but
outside the C-type lectin region, antisense
35 oligonucleotide, 439 A/S (SEQ ID NO: 24), which was
directed against the sequence upstream of the open reading.

a: cocultures treated with anti-sense

oligonucleotide under basal conditions.

b-d: cocultures stimulated with anti-sense
oligonucleotides 323 A/S (SEQ ID NO: 22), 402 A/S (SEQ ID
NO: 23), 439 A/S (SEQ ID NO: 24) and 474 A/S (SEQ ID NO:
5 25), in the presence of 1,25-dihydroxyvitamin D₃ and PGE₂.

Figure 11 shows the results of Northern blot
analysis of mRNA from UMR106 parental cells, demonstrating
upregulation of expression of OCIL by retinoic acid, PTH,
IL-1 α , IL-1 β , IL-11, IL-17, TNF α , TGF β , M-CSF, GM-CSF,
10 PGE₂, 1,25-dihydroxy-vitamin D₃, 1,25-dihydroxyvitamin D₃
plus PGE₂, and PGE₂ plus dexamethasone.

Figure 12A shows the results of a time-course
study, showing upregulation of OCIL by PTHrP.

Figure 12B shows that the upregulation could be
15 detected using either rOCIL402 or mOCIL 2kb as the probe.

Figure 13 shows upregulation of expression of
OCIL in primary mouse calvarial osteoblasts by IL-1 α ,
IL-1 β , IL-11, dexamethasone, and 1,25-dihydroxyvitamin D₃.

Figure 14A shows upregulation of expression of
20 OCIL in ST2 mouse stromal cells by PGE₂, dexamethasone,
1,25-dihydroxyvitamin D₃, IL-11, PTH, and 1,25-dihydroxy-
vitamin D₃ plus PGE₂.

Figure 14B shows the time course of upregulation
of OCIL expression in ST2 cells by dexamethasone.

25 Figure 15 shows the constitutive expression of
mOCIL and mOCILrP1/rP2 mRNA during osteoclast formation in
mouse bone marrow cell cultures.

Figure 16 shows the results of Northern blot
analysis of adult mouse tissues (left panel) and adult rat
30 tissues (right panel), demonstrating expression of OCIL.

Figure 17 shows a schematic comparison between
the sequences of rOCIL402, rOCIL1.3kb, rOCIL323 and rOCIL,
illustrating differences between the 3' and 5' end regions.

Figure 18a compares the exon structures of four
35 different hOCIL clones.

Figure 18b shows the deduced protein sequences
corresponding to hOCIL clone 3, illustrating the domain

structure of the protein.

Figure 19 is a schematic representation of plasmid constructs used for recombinant expression of soluble mOCIL (Figure 19a) and soluble rOCIL (Figure 19b).

5 Figure 20 shows the effect of recombinant rOCIL (Figure 20a) protein or mOCIL protein (Figure 20b) on formation of multinucleate osteoclasts from mouse calvarial osteoblast-spleen cell cocultures.

10 Figure 21 shows the effects of hM-CSF and sRANKL in the absence or presence of mOCIL protein on osteoclast formation in mouse spleen cell cultures.

Figure 22 is a schematic representation of a plasmid construct used for recombinant expression of an MBP-mOCIL fusion protein.

15 Figure 23 is a schematic representation of a plasmid construct used for recombinant expression of an MBP-mOCILrP1 fusion protein.

20 Figure 24 is a schematic representation of a plasmid construct used for recombinant expression of an MBP-mOCILrP2 fusion protein.

Figure 25 is a schematic representation of a plasmid construct used for recombinant expression of an MBP-hOCIL fusion protein.

25 Figure 26 shows the effects of hM-CSF and sRANKL in the absence or presence of MBP or MBP-mOCIL fusion protein on osteoclast formation in total spleen cell (Figure 26a) or T cell-depleted mouse spleen cell cultures (Figure 26b).

30 Figure 27 shows the effects of hM-CSF and sRANKL in the absence or presence of the fusion proteins MBP-mOCILrP1 (Figure 27a) and MBP-mOCILrP2 (Figure 27b) on osteoclast formation in T cell-depleted mouse spleen cell cultures.

35 DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described in detail by way of example only, with reference to the following non-

- 11 -

limiting examples and drawings.

We set out to clone a gene encoding a peptide that would function to prevent osteoclast formation. It is known that mature osteoblasts have limited potential to support osteoclast formation, and we postulated that mature osteoblasts might express osteoclastogenic inhibitors. The pre-osteoblastic cell line UMR201 can be differentiated to a more mature osteoblastic phenotype by treatment with 10^{-6} M retinoic acid for 24 hr (Ng et al, 1988). mRNA species differentially expressed between mature osteoblasts (retinoic acid-treated UMR201 cells) and immature osteoblasts (untreated UMR201 cells) were identified using an array of oligonucleotide primers in reverse transcription PCR, where products amplified from RNA from the two cellular populations were compared. We characterised products which were elevated in mature osteoblasts as candidates for osteoclastogenic inhibitory molecules.

Abbreviations used herein are as follows:

| | | |
|----|--------------------------------------|--|
| 20 | GM-CSF | granulocyte/macrophage colony stimulating factor |
| | hPTH | human parathyroid hormone |
| | IGF | insulin like growth factor |
| | IL | interleukin |
| 25 | LIF | leukaemia inhibitory factor |
| | M-CSF | macrophage colony stimulating factor (CSF-1) |
| | 1,25(OH) ₂ D ₃ | 1,25-dihydroxyvitamin D ₃ |
| | OCIF | osteoclastogenesis inhibitory factor |
| | ODF | osteoclast differentiation factor |
| 30 | OPG | osteoprotegerin |
| | PCR | polymerase chain reaction |
| | PGE ₂ | prostaglandin E ₂ |
| | PTH | parathyroid hormone |
| | PTHrP | parathyroid hormone-related protein |
| 35 | RANK | Receptor activator of NF- κ B |
| | RANKL | Receptor activator of NF- κ B ligand |
| | TGF | transforming growth factor |

- 12 -

TNF tumour necrosis factor
TRAP tartrate-resistant acid phosphatase.

- 13 -

Throughout this specification amino acids are represented using the conventional single-letter code.

Example 1: Isolation of Rat cDNA Encoding the Inhibitory Factor

5 Total RNA was isolated from retinoic acid-treated preosteoblastic UMR201 cells using guanidine thiocyanate (Chomczynski et al, 1987). First strand cDNA was synthesised from 2 µg of total RNA by incubating for 1 h at 10 42°C with 15 units of AMV reverse transcriptase (Promega, Madison, WI) following oligo priming with the 3' adaptor primer 5'-GGC CAC GCG TCG ACT AGT ACT TTT TTT TTT TTT T-3') (Clontech, California, USA). A sense primer that was complementary to rat calcitonin cDNA, designated primer 15 CT1:

CT1 5'-ATG CTG GGC ACG TAC ACA CAA-3' (SEQ ID NO:1)

20 and 3'UAP 5'- GGC CAC GCG TCG ACT AGT AC-3' (Clontech, California, USA) were used as primers in the polymerase chain reaction (PCR). The PCR conditions utilised a touchup PCR protocol with denaturation at 94°C for 5 min, and then 5 cycles at 94°C for 1 min, 37°C for 1 min and 25 72°C for 1 min, followed by 35 cycles of 94°C for 1 min, 49°C for 1 min and 72°C for 1 min. For these experiments, Expand High Fidelity PCR System (Boehringer Mannheim) was used in a Perkin Elmer Cetus 480 thermal cycler. A 321 bp PCR product was obtained. This 321 bp fragment, which we 30 designated ROCIL323 (SEQ ID NO: 2), was used as a probe in Northern blots. As shown in Figure 2, it hybridised to a 780 bp mRNA species in UMR 201, UMR 201-10B, UMR 106-06, UMR 106-01 and ROS 17/2.8 cells, all of which are rat clonal osteoblast-like cell lines.

35 Since retinoic acid and PTH enhance OCIL mRNA expression dramatically in UMR 106-06 and UMR 106 parental cells, a similar RT-PCR procedure was carried out using RNA

- 14 -

isolated from retinoic acid or hPTH 1-34 treated UMR 106 parental cells. A PCR product identical to the 321 bp fragment for rOCIL323 was obtained, and its expression was found to be upregulated in UMR 106 cells treated with

5 either retinoic acid or hPTH 1-34.

To extend the sequence of OCIL, anchored PCR was used to screen a rat ROS 17/2.8 cDNA library with λ gt11 arms. An antisense 25 bp primer, designated OCILr1:

10 OCILr1 5'-TGA GTG TTG TCT GTC CAC TTC CAA G-3' (SEQ ID NO: 3)

complementary to a sequence in the 321 bp fragment, was used with either the λ gt11 forward primer

15 5'-GGT GGC GAC GAC TCC TGG AGC C-3' or λ gt11 reverse primer 5'-GAC ACC AGA CCA ACT GGT AAT G-3' (Clontech) to amplify an aliquot (10^6 plaque forming units) of the recombinant library. Cycling parameters were 94°C for 5 min, then 80 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 20 2 min, followed by a final extension step of 72°C for 10 min. A 402 bp fragment was obtained with λ gt11 reverse primer as the anchored primer. Sequencing of this 402 bp fragment showed 88.6% identity over a length of 97 bp with rOCIL323 (SEQ ID NO: 2). The 402 bp fragment, designated 25 rOCIL402, whose sequence is set out in SEQ ID NO: 4, was used to probe Northern blots obtained from the rat osteoblast-like cell line. It hybridised to the same 780 bp mRNA species observed with the rOCIL323 probe. These results are shown in Figures 3 and 4. The same 30 results were obtained in both the presence and absence of 1,25-dihydroxyvitamin D₃.

A 3' Rapid Amplification of cDNA Ends (3'-RACE) strategy was used to obtain the 3' ends of the cDNA of interest. First-strand cDNA was synthesised from total RNA 35 isolated from hPTH 1-34 treated UMR 106 parental cells by incubating for 1 h at 42°C with 15 units of AMV reverse transcriptase (Promega, Madison, WI) following priming with

- 15 -

the 3' adaptor primer 5'-GGC CAC GCG TCG ACT AGT ACT TTT TTT TTT TTT T-3') (Clontech, California, USA) according to the manufacturer's instructions. The sense specific primers used were OCILr11 (SEQ ID NO: 5)

5

OCILr11 5'-GAA ACA TCC CCC TGG AGT ATC C-3'

and OCILr12 (SEQ ID NO: 6)

10 OCILr12 5'-CCA AGT AAC TGG ACA TTG AGC CAG A-3'

complementary to sequences within rOCIL402 (SEQ ID NO: 4). First-strand cDNA was synthesised from total RNA isolated from hPTH 1-34 treated UMR 106 parental cells, using the
15 oligo dT-anchor primer. The cDNA was further amplified by PCR using OCILr11 or OCILr12 and 3'UAP 5'-GGC CAC GCG TCG ACT AGT AC-3' (Clontech, California, USA) PCRs were run at 94°C for 5 min, then 35 cycles of 94°C for 30 s, 62°C for 30s, and 72°C for 2 min, followed by a final extension step
20 of 72°C for 10 min. Three different polyadenylated 3' sequences were obtained, designated rOCIL1.3kb (SEQ ID NO: 7), rOCIL738bp (SEQ ID NO: 8) and rOCIL620bp (SEQ ID NO: 9) respectively. The region of sequence identity between rOCIL323 and rOCIL402 was found to extend to 117
25 bp.

Example 2: Isolation of Mouse cDNA and gDNA Encoding the Inhibitory Factor

30 rOCIL402 was labelled with [³²P] α-dCTP by using the Random Primer labelling kit (Boehringer Mannheim), and a mouse liver cDNA library was subjected to hybridisation screening at 65°C in a hybridisation buffer containing 4 x SSPE (SSPE contains 0.15 M NaCl, 0.01 M NaH₂PO₄, and 0.001 M EDTA), 5 x Denhardt's solution, 0.5% sodium dodecyl
35 sulfate (SDS) for 24 hr. The filters were then washed sequentially in 2 x SSC at 65°C for 15 min, 2 x SSC with 0.1% SDS at 65°C for 30 min, and finally 0.1 x SSC at 65°C

- 16 -

for 10min. We obtained a 1907bp mouse cDNA, designated mOCIL2kb (SEQ ID NO: 10). The sequence of mOCIL2kb shows 80% identity over a length of 461 bp to that of rOCIL1.3kb. When used as an antisense riboprobe in Northern blot

- 5 analysis, mOCIL2kb hybridised to a 780 bp mRNA species in UMR201 as detected by rOCIL323 and rOCIL402, as shown in Figure 5.

- A cDNA fragment corresponding to the nucleotides 58-776 of mOCIL2kb was used as a cDNA probe to screen a
10 genomic BAC Mouse I Hybridisation library. The screening was performed under contract by Genome Systems, Inc. According to their protocol, the cDNA fragment was labelled with [³²P] α -dCTP by random primer labelling and the library was screened under the hybridisation conditions of
15 55°C in a hybridisation buffer containing 5.5 x SSC, 5 x Denhardt's solution, 0.5% SDS and 0.5 x HEPES buffer for 18 hr. The filters were then washed sequentially in 1mM Tris-HCl pH 8.0 and 1% sarkosyl for 15 min, and 3 times in 1mM Tris-HCl pH 8.0 for 15 min washes at room temperature.
20 Eight positive clones were isolated, of which seven positive clones were screened. After the genomic DNA was digested with HindIII or BamHI, Southern blot analyses were carried on with the same cDNA probe. Four clones (db.20147, db.20149, db.20151 and db.20152) were related,
25 and other clones (db.20150, db.20153 and db.20154) are yet to be extensively analysed. The clones db.20147 and db.20149 were identical, and these differed from the other two identical clones db. 20151 and db.20152. These four clones were sequenced by subcloning into the pBS vector and
30 by direct sequencing of the genomic clone using cycle sequencing. Sequencing of 8622 bp of the genomic clone (db.20152) of mOCIL was completed (SEQ ID NO: 37). It contains 5 exons, as shown in Figure 6. The 5' flanking region adjacent to exon I contains an A/T-rich motif,
35 AATAAA, as TATA box gene promoter. Sequencing of 9862 bp of the genomic clone (db. 20149) was also completed (SEQ ID NO: 11). It contains 6 exons, as shown in Figure 6. The

- 17 -

sequences of exons I and II were completely different to that of mOCIL exon 1. The sequence of exons III to VI was 90.28% identical to that of mOCIL from exon II. The 5' flanking region adjacent to exon I is a GC-rich region, containing a Sp 1 binding site. In combination, these features indicated that in fact this was a different gene. A search of the GenBank database showed that exons I and II showed 100% identity to a cDNA clone encoding a C-type lectin expressed in mouse bone marrow-derived dendritic cells, which was deposited in the GenBank data base on 20 January 1999 (Accession No. AF121352) and released on 15 June 1999. However, exons III to VI are 92% identical to AF121352 cDNA. The sequence of this genomic clone is redesignated as mOCIL-related protein 1 (mOCILrP1) gene (SEQ ID NO:11). The full length mOCILrP1 cDNA was originally thought to be a spliced variant of mOCIL, and is 990 bp in length (SEQ ID NO: 12).

To confirm the mOCIL (SEQ ID NO: 36) and mOCILrP1 (SEQ ID NO:12) cDNA sequences, RT-PCR was carried out using total RNA isolated from ST2 mouse stromal cells, primary mouse calvarial osteoblasts and mouse liver tissue. The sense primer represented nucleotides 18-36 of mOCILrP1 (SEQ ID NO:12), and is designated as primer OCILm47 (SEQ ID NO: 13),

OCILm47 5'- TCC CAT GCC AGA TTG CTT G-3'

The antisense primer, which was originally designed from mOCIL2kb (SEQ ID NO: 10) nucleotides 136-157, represented nucleotides 746-725 of mOCIL (SEQ ID NO: 36) and is designated primer OCILm12 (SEQ ID NO: 14),

OCILm12 5'-GGG ACC ATA GGG GAA AGA GTA G-3'

The PCR was run at 94°C for 5 min, then 35 cycles of 94°C for 30s, 60°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. Seven clones

- 18 -

containing a 721 bp fragment were obtained from three sources, ST2 mouse stromal cells, primary mouse calvarial osteoblasts and mouse liver tissue. In 2 of the 7 clones, there was 100% identity to mOCILrP1 sequence, and 92.2% identity to mOCIL after the first 115 bp. In the other 5 clones, when compared to the mOCILrP1 sequence, there was 100% identity in the first 106 bp (exons I and II), but only 90.5% identity in the remaining 615 bp. This 721 bp fragment, originally designated as mOCIL47, was redesignated as mOCILrP2 (SEQ ID NO: 15). mOCILrP2 is related to, but distinct from, mOCIL (SEQ ID NO: 36) and mOCILrP1 (SEQ ID NO: 12).

A sense primer representing nucleotides 343-364 of mOCIL2kb (SEQ ID NO:10) and representing nucleotides 34-57 of mOCIL (SEQ ID NO:36), designated as OCILm17 (SEQ ID NO: 16),

OCILm17 5'-TGG AAA CTC AGC TCC TCA GCT CTG-3'

and antisense primer OCILm12 were also used to carry out RT-PCR with RNA from three sources, ST2 mouse stromal cells, primary mouse calvarial osteoblasts and mouse liver tissue, as above. PCR was run under the same conditions as above. Ten clones were obtained, each containing a 713 bp fragment. This sequence is designated mOCIL17 (SEQ ID NO: 17), and is 100% identical to mOCIL (SEQ ID NO: 36).

RT-PCR was also carried out using a sense primer corresponding to the region located at the junction of exons II and III, representing nucleotides 245-269 of mOCIL (SEQ ID NO: 36) and at the junction of exon III and exon IV, representing nucleotides 243-267 of mOCILrP1 (SEQ ID NO: 12), and designated primer OCILm32 (SEQ ID NO: 18),

OCILm32 5'- TTT GTC AGC AAC AAA GAC AGA ACA G-3'

35

The primer oligonucleotide OCILm32 has 23 of 24 bp complementary to mOCILrP1:

- 19 -

5'-TTTGTCTAGCAACAAGACAGAACAG-3' Primer

||||||| ||||||||||||||||

3'-AAACAGTCATGTGTTCTGTCTTGTC-5' mOCILrP1 (267) Strand -

5

Primer OCILm12 was used as an antisense primer. RT-PCR was carried out with RNA from three sources, ST2 mouse stromal cells, primary mouse calvarial osteoblasts and mouse liver tissue, as above. PCR was run under the same conditions. Four clones were obtained, each containing a 502 bp fragment. Three of the four clones have 100% identity to mOCIL (SEQ ID NO: 36) and one of the four clones is 100% identical to mOCILrP1 (SEQ ID NO: 12).

RT-PCR was also carried out using the sense primer OCILm47 (SEQ ID NO: 13) and an antisense primer representing nucleotides 855-874 of mOCILrP1 (SEQ ID NO: 12), designated primer OCILm49 (SEQ ID NO: 38),

OCILm49 5'-GTG GTT GCT CAG ATG TGA AC-3'

20

RT-PCR was carried out with RNA from the same three sources, ST2 mouse stromal cells, primary mouse calvarial osteoblasts and mouse liver tissue, as above. PCR was run under the same conditions. Two clones were obtained, each containing a 856 bp fragment with 100% identity to AF121352 and in which the first 713 bp are 100% identical to mOCILrP2 (SEQ ID NO: 15).

To further confirm that mOCILrP2 is AF121352, an antisense primer was designed based on the sequence of AF121352 (nucleotides 908-929), designated as primer OCILm48 (SEQ ID NO: 39),

OCILm48 5'-TTC ACA CAT CCC AGA AGA GGA C-3'

OCILm47 (SEQ ID NO: 13) was used as sense primer. RT-PCR was carried out under same conditions as above. Two clones were obtained, each containing a 916 bp fragment which has

- 20 -

100% identity to AF121352 and in which the first 713 bp is 100% identical to mOCILrP2 (SEQ ID NO: 15).

The full length mOCILrP2 cDNA is 988 bp in length. Its first 123 bp is 100% identical to mOCILrP1, but
5 only 91.7% identical in the remaining 865 bp. Figure 7 summarises the homology between mOCIL, mOCILrP1 and mOCILrP2. The three different sequences (SEQ ID NO: 12, 15 and 36), which overall have 87% identity, may represent gene duplications, where either one or all three sequences
10 may have similar biological outcomes. The functional data we have to date, relating to the inhibition of osteoclast formation from haemopoietic precursor cells using antisense oligonucleotides (SEQ ID NO: 24 and 25), have been obtained mainly with mOCIL17 (SEQ ID NO: 17), although experiments
15 with recombinant protein (see below) indicate that the extracellular domains of mOCIL, mOCILrP1 and mOCILrP2 respectively can inhibit osteoclast formation.

mOCIL has an open reading frame encoding a 207 amino acid protein. As shown in Figure 8a, its
20 putative protein structure is typical of a type II membrane protein, with a predicted 143 amino acid extracellular domain, a 21 amino acid transmembrane domain, and a 43 amino acid cytoplasmic domain. The extracellular domain has 5 cysteine residues. There are three potential
25 N-linked glycosylation sites at residues 74, 100 and 158, all of which are in the extracellular domain. The putative protein sequence for mOCIL is designated mOCIL protein (SEQ ID NO: 40).

Comparison of the putative protein sequences
30 derived from the rOCIL323, rOCIL1.3kb and mOCIL cDNA sequences with the SwissProt protein database indicated that the mOCIL protein sequence included an 113 amino acid C-lectin type motif, from positions 80 to 192 in the mOCIL protein sequence (SEQ ID NO: 40). This C-lectin motif is
35 similar to that of CD69, a membrane-bound lectin expressed by bone marrow haematopoietic cells, and thought to be involved in monocyte differentiation. C-lectin motifs are

- 21 -

also involved in cell-cell contact and lipid binding (Sharon and Lis, 1995; Gabius 1997; Kieda, 1998).

mOCILrP1 has an open reading frame encoding a 218 amino acid protein. The putative protein sequence for
5 mOCILrP1 is designated mOCILrP1 protein (SEQ ID NO: 41). Its structure is also typical of a type II membrane protein, with a predicted 142 amino acid extracellular domain, a 21 amino acid transmembrane domain, and a 55 amino acid cytoplasmic domain. The mOCILrP1 protein
10 sequence also has a 113 amino acid C-lectin type motif, from positions 92 to 204 in the mOCILrP1 protein sequence (Figure 8b). The extracellular domain has 6 cysteine residues. There are three potential N-linked glycosylation sites at residues 86, 112 and 207, all of which are in the
15 extracellular domain. There is a myristylation motif in the intracellular domain.

mOCILrP2 has an open reading frame encoding a 217 amino acid protein. The putative protein sequence for mOCILrP2 is designated mOCILrP2 protein (SEQ ID NO: 42).
20 Its structure is also that of a type II membrane protein, with a predicted 141 amino acid extracellular domain, a 21 amino acid transmembrane domain, and a 55 amino acid cytoplasmic domain. Similarly to mOCIL and mOCILrP1, the mOCILrP2 protein sequence has an 113 amino acid C-lectin
25 type motif, from positions 92 to 204 in the mOCILrP2 protein sequence (Figure 8c). The extracellular domain has 6 cysteine residues. There are four potential N-linked glycosylation sites at residues 86, 95, 112 and 165, all of which are in the extracellular domain.

30 The three different mouse protein sequences (SEQ ID NO: 40, 41 and 42) overall have 89% identity as shown in Figure 9. There are differences in the intracellular domains between mOCIL and mOCIL-related proteins, and these domains may have different functional roles. If the C-type
35 lectins act as receptors, the intracellular domains may confer different properties as a result of signal transduction. Comparison of the protein sequences in the

- 22 -

intracellular domain against the PROSITE database, using the ScanProsite program, showed that mOCIL protein has a Casein Kinase II (CK2) phosphorylation site at position 16-19 in SEQ ID NO: 40. In contrast, mOCILrP1 protein has two Protein Kinase C (PKC) phosphorylation sites at positions 42-44 and 51-53 (SEQ ID NO: 41), while mOCILrP2 (SEQ ID NO: 42) has no phosphorylation sites.

The three different proteins, mOCIL, mOCILrP1 and mOCILrP2, may be distinguished by several criteria:

(a) Nucleotide sequence: mOCIL, mOCILrP1 and mOCILrP2 appear to be derived from a common ancestral gene; however there are nucleotide differences which permit identification of the three molecules using specific oligonucleotide primers in RT-PCR, as described in Example 5, Figure 15.

(b) Gene structure: The promoter of mOCIL is a TATA promoter (SEQ. ID. No. 37), while the promoter for mOCILrP1 is a GC-rich region containing a SP 1 binding site (SEQ. ID. No. 11).

(c) mOCIL expression is regulated by PTH, while the expression of mOCILrP1 and mOCILrP2 is not (see example 5).

(d) The polypeptide products of mOCIL, mOCILrP1 and mOCILrP2 can be distinguished using antibodies directed against peptide fragments of mOCIL (SEQ. ID. No. 48) and mOCILrP1/rP2 (SEQ. ID. No. 49) based on the intracellular domains of the respective proteins. These have been used in tissue localisation studies, as described in Example 6.

Example 3: Isolation of Human cDNA Encoding the Inhibitory Factor

[³²P] α -dCTP labelled rOCIL402 was used to probe a human fetal cDNA library under low stringency hybridisation conditions at 55°C in a hybridisation buffer containing 4 x SSPE, 5 x Denhardt's solution, 0.5% SDS for 24 hr, and then washed with low stringency at 2 x SSC with 0.1% SDS at 40°C for 15 min, and 1 x SSC/0.1% SDS at 40°C

- 23 -

for 15min. Eight positive clones were obtained after tertiary screening. Clone No. 6 is a 1.3 kb cDNA segment, whose sequence was designated hOCIL clone 6 (SEQ ID NO: 19). The putative protein sequence encoded by bp883-1059 was a C-type lectin moiety, which showed 73% homology to the C-type lectin sequence previously demonstrated in rOCIL323, rOCIL1.3kb and mOCIL2kb. However, regions of amino acid sequence 5' and 3' to this C-type lectin domain were different from those of the mouse and rat sequences, as shown in Figure 6.

Clone No. 8 is 960 bp long. It has 64% identity over a length of 145 bp with rOCIL402. A search of the EST database showed that clone No. 8 has 99.5% sequence identity with an EST clone of unknown function from human pregnant uterus, Accession No. AA029932, over the published length of this EST 209 bp. This EST clone was ordered and further sequenced. The EST clone is 680 bp in length, and has 64% identity with rOCIL1.3kb over a length of 343 bp. It also has 64% identity over a length of 346 bp compared to mOCIL. RT-PCR showed that clone No 8 and AA029932 represent overlapping clones, which are contiguous, and combine to represent a human OCIL clone 1 of 1305 bp in length (SEQ ID NO: 20).

The deduced protein sequence has 56% homology to the deduced protein sequence of rOCIL1.3kb, and 52% homology to that of mOCIL. These differences are principally at the N-terminus. Although there is 80% homology between the mouse and human OCIL proteins in certain regions, this indicates that the mouse cDNA could not reliably be used to isolate a human genomic DNA encoding hOCIL.

In order to obtain the hOCIL gene, the 680 bp cDNA insert of clone AA029932 was isolated and screened by Genome Systems, Inc. against the genomic BAC Human Release II Hybridisation library, as described in Example 2. One positive clone was obtained. This genomic sequence, corresponding to the sequence from 654bp-1304bp of hOCIL,

- 24 -

has 100% identity to a sequence segment within a human genomic clone OF 178,607 bp, which was deposited in the GenBank database on April 6, 1999 (Accession No. AC007068), and the 5' flanking region, promoter region and the first
5 654 bp of cDNA sequences are represented in the 74,801 bp sequence deposited in the GenBank database on December 9, 1999 (Accession No. AC010186).

The hOCIL gene is located in chromosome 12p. Chromosome 12 and chromosome 11 are considered to be
10 evolutionarily related. There are several examples of evolutionarily related proteins whose genes are located on chromosome 12 and chromosome 11, such as PTH and PTHrP, IGF and IGF I, Harvey ras sarcoma 1, and Kisten ras sarcoma 2, etc. (Martin et al., 1991). Thus chromosome 11 and
15 chromosome 12 share genes of similar biological characteristics with redundant function.

Example 4: Effect of Anti-Sense Oligonucleotides on Osteoclast Formation

20 Primary mouse calvarial osteoblasts were cocultured with mouse bone marrow cells to generate mononuclear and multinucleate osteoclasts. Staining for tartrate-resistant acid phosphatase (TRAP), performed using a commercial leukocyte acid phosphatase kit from Sigma
25 Diagnostics (St. Louis, MO, USA; Katsogiannis et al, 1998), identified these cells as osteoclasts. Under normal conditions, multinucleate functional osteoclasts are not formed unless the cocultures are stimulated with 1,25-dihydroxyvitamin D₃ and PGE₂.

30 Experiments were carried out to block translation of OCIL mRNA in order to determine the function of its translated product. Antisense oligonucleotides may also down-regulate mRNA levels, and thus may effectively decrease transcription as well as translation. Primary
35 mouse calvarial osteoblasts were treated with antisense oligonucleotides. Four antisense oligonucleotide sequences were designed. Two of these antisense oligonucleotide

- 25 -

sequences were complementary to the C-type lectin region, and designated 323 (SEQ ID NO: 22) and 402 (SEQ ID NO: 23) respectively:

5 323 5'-GAG TGT TGT CTG TCC ACT TCC-3'

402 5'-TTT CCA ACT CCA ATC CAG TTT-3'

The 323 antisense oligonucleotide has 19 of 21 bp
10 complementary to mOCILrP2 (SEQ ID NO: 15)

5'-GAGTGTGTGTCTGTCCACTTCC-3' 323 antisense (SEQ ID NO: 22)

||||||| |||||||||

3'-GTCACAACAACAGGTGAAGG-5' mOCILrP2 Strand +

15 and has 20 of 21 bp complementary to mOCILrP1 (SEQ ID
NO: 12)

5'-GAGTGTGTGTCTGTCCACTTCC-3' 323 antisense (SEQ ID NO: 22)

20 ||||||| |||||||||

3'-GTCACAACAGACAGGTGAAGG-5' mOCILrP1 Strand +

and 100% to mOCIL (SEQ ID NO: 36)

25 5'-GAGTGTGTGTCTGTCCACTTCC-3' 323 antisense (SEQ ID NO: 22)

||||||| |||||||||

3'-GTCACAACAGACAGGTGAAGG-5' mOCIL Strand +

The 402 antisense oligonucleotide (SEQ ID NO: 23) has 100%
30 complementarity to mOCILrP1 (SEQ ID NO: 12) and has 20 of
21 bp complementary to mOCILrP2 (SEQ ID NO: 15) and mOCIL
(SEQ ID NO: 36):

5'-TTTCCAATCCAATCCAGTTT-3' 402 antisense (SEQ ID NO: 23)

35 ||||||| |||||||

3'-AAAGGTTGAGGTGAGGTCAAA-5' mOCILrP2 Strand +

- 26 -

5'-TTTCCAACCTCCAATCCAGTTT-3' 402 antisense (SEQ ID NO: 23)

||| ||||||||||||||||

3'-AAAAGTTGAGGTTAGGTCAAA-5' mOCIL Strand +

5 The other two antisense oligonucleotide sequences, respectively designated 439 (SEQ ID NO: 24) and 474 (SEQ ID NO: 25), specifically inhibit the translation of mOCIL (SEQ ID NO: 36) but not mOCILrP1 (SEQ ID NO: 12) and mOCILrP2 (SEQ ID NO: 15).

10 The oligonucleotide 439 (SEQ ID NO: 24) is antisense to the sense primer OCILm17 and located upstream of the open reading frame:

439 5' GAG GAG CTG AGT TTC CAC TAC-3'

15 The antisense oligonucleotide 474 (SEQ ID NO: 25) is complementary to a region in mOCIL17 (SEQ ID NO: 17) in the open reading frame in the intracellular domain but outside the C-type lectin region:

20 474 5'-GGT AGG GAA GCC TTT GTG AC-3'.

 Under basal conditions, *ie.* in the absence of stimulation with 1,25-dihydroxyvitamin D₃ and PGE₂, there was a 3- to 5-fold increase in the number of mononucleate TRAP-positive cells in the cocultures treated with the 323 (SEQ ID NO: 22) and 474 (SEQ ID NO: 25) antisense oligonucleotides over the period from 3 to 7 days. With the 402 antisense oligonucleotide (SEQ ID NO: 23), a 4.5-fold increase in the formation of mononucleate TRAP positive cells was observed after 7 days treatment. Multinucleate TRAP-positive cells (323 (SEQ ID NO: 22); 4.5 ± 2, 474 (SEQ ID NO: 25); 4.25 ± 1.25) were also observed in cocultures treated with both 323 (SEQ ID NO: 22) and 474 (SEQ ID NO: 25) antisense oligonucleotides at a concentration of 5µM, whereas none were observed in the control. These experiments were performed three times, and

a representative result is shown in Figure 10a.

When the cocultures were stimulated with 1,25-dihydroxyvitamin D₃ and PGE₂, multinucleate TRAP-positive osteoclasts were formed after 7 days. Treatment
5 with 5 μM 323 antisense oligonucleotide (SEQ ID NO: 22) resulted in a seven-fold increase in the number of multinucleate osteoclasts, as shown in Figure 10b.

Treatment with 10 μM 402 (SEQ ID NO: 23), 5 μM 439 (SEQ ID NO: 24) and 474 (SEQ ID NO: 25) antisense
10 oligonucleotide resulted in a 2 to 3-fold increase in the formation of multinucleate osteoclasts after 7 days, as shown in Figures 10c and 10d.

These TRAP-positive cells were further characterized as osteoclasts by the presence of receptors
15 for calcitonin, demonstrated using autoradiography and immunostaining, and by the ability of these cells to form resorption pits in bone slices.

Effects of mOCIL antisense oligonucleotides on the three phases of osteoclast formation were also
20 investigated. Mouse bone marrow and primary osteoblastic cells were cocultured in the absence of 1,25-dihydroxyvitamin D₃ and PGE₂ for a 7 day culture period. 323 (SEQ ID NO: 22) and 474 (SEQ ID NO: 25) antisense oligonucleotides were added for the 3 phases of
25 culture: the first phase (0-3 days), in which there is proliferation of osteoclast progenitors, the second phase (3-5 days) and the final phase (5-7 days), in which these cells differentiate into mature osteoclasts. TRAP-positive osteoclasts were counted. In order to examine the role of
30 OCIL on the bone resorptive activity of mature osteoclastic cells, the cells were also cultured on dentine slices under the same culture conditions as above, and resorption pits formed on dentine slices were quantitated. The results are shown in Table 1, and indicate that the OCIL acted at an
35 early stage in osteoclast formation.

Table 1
Effects of mOCIL Antisense Oligonucleotides on the Three Phases of Osteoclast Development

| TIME | TREATMENT | MONO | MNC | PITS |
|----------|-----------|-----------------|-------------|-------------|
| 7 days | control | 3596 ± 511.5 | 0 | 10 ± 4.4 |
| 0-3 days | 323 | 6880 ± 674 * | 7.7 ± 5.3 | 34 ± 15 |
| | 474 | 6893 ± 429.6 ** | 8.7 ± 1.7 * | 20 ± 2.5 |
| 3-5 days | 323 | 2840 ± 197.6 | 0 | 14 ± 6 |
| | 474 | 3110 ± 334 | 4.3 ± 2 | 24 ± 2.5 * |
| 5-7 days | 323 | 4236 ± 518.6 | 0 | 10.6 ± 0.79 |
| | 474 | 3363 ± 139.8 | 0 | 3.3 ± 2 |
| 0-7 days | 474 | 5223 ± 571 * | 3.3 ± 1 | 20.3 ± 5.9 |

mono mononuclear osteoclast precursors
MNC multinucleate osteoclasts
pits resorption pits formed on dentine slices
* $p < 0.05$ vs. control
** $p < 0.01$ vs. control

- 29 -

Example 5: Regulation of expression of OCIL mRNA

The regulation of OCIL mRNA expression was examined in the UMR106 parental osteoblast-like cell line using rOCIL402 as a probe. As shown in Figure 11, expression of the mRNA was upregulated by retinoic acid (RA), parathyroid hormone (1-34), parathyroid hormone related protein (1-34), TNF- α , interleukin 1 α (IL-1 α), IL-1 β , IL-11, IL-17, GM-CSF, M-CSF, TGF β , dexamethasone, 1,25-dihydroxyvitamin D₃ and prostaglandin E₂. A time course study, illustrated in Figure 12, showed that parathyroid hormone-related protein (1-34) increased levels of OCIL mRNA as early as 1 hour, peaking at 4 hours and maintaining the high level of expression until 48 hours.

As shown in Figure 13, in primary mouse calvarial osteoblasts, OCIL mRNA was upregulated by IL-1 α , IL-1 β , IL-11, 1,25-dihydroxyvitamin D₃ and retinoic acid. In ST2 mouse stromal cells, OCIL mRNA was upregulated by dexamethasone, 1,25-dihydroxyvitamin D₃ and IL-11. The time course also showed that dexamethasone increased OCIL mRNA at 1 hour, peaking at 2 hours and returning at basal level at 24 hours. These results are illustrated in Figures 14A and 14B, respectively.

Example 6: OCIL mRNA expression during osteoclast formation in mouse marrow cultures

OCIL mRNA expression during osteoclast formation in mouse marrow cultures was investigated by RT-PCR. The mouse bone marrow cells were prepared and cultured for 8 days in the presence of 1,25-dihydroxyvitamin D₃, as described by Ikegame et al (1995). At each time point, total RNA was isolated. RT-PCR was carried out using OCILm17 (SEQ ID NO: 16) and OCILm12 (SEQ ID NO: 14) as sense and antisense primers respectively. The PCR was run at 94°C for 5 min, then 30 cycles of 94°C for 30s, 60°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. RT-PCR was also carried out to investigate mOCILrP1/rP2 mRNA expression during such

- 30 -

cocultures. Primers specific for mOCILrP1/rP2, which distinguish these from mOCIL, were OCILm47 (SEQ ID NO: 13), a sense primer located on the intracellular domain of mOCILrP1 and mOCILrP2, and OCILm12 (SEQ ID NO: 14) as an antisense primer. The PCR was run at 94°C for 5 min, then 30 cycles of 94°C for 30s, 60°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. Southern blot analysis was carried out as described by Zhou et al (1994); 20 µl of each PCR reaction mixture was run on a 2% agarose gel, transferred to nylon membranes, and the products authenticated by probing with an internal antisense strand oligonucleotide, OCILr1 (SEQ. ID NO: 3). OCILr1, which has 24 of 25 bp complementary to mOCIL and mOCILrP1 and 23 of 25 bp complementary to mOCILrP2, was labelled with digoxigenin-dUTP using a 3'-tailing kit (Boehringer Mannheim). Hybridisation was carried out with 2 pmol/ml labeled oligonucleotides in a buffer containing 5 x SSC, 0.02% SDS, 0.1% sarcosine and 100 ng/ml poly A, at 55°C for 14 h. Detection was by chemiluminescence using CDP-star (Boehringer Mannheim), according to the manufacturer's instructions.

For comparison with another osteoclast inhibitor, OPG mRNA expression was also investigated. A set of sense and antisense primers was used as described by Horwood et al. (1998), having nucleotide sequences represented by OPG-7 (5'-TGAGTGTGAGGAAGGGCGTTAC-3', nucleotides 405-426) and OPG-3 (5'-TTTCTCGTTCTCTCAATCTC-3', nucleotides 1021-1040), respectively. The PCR was run at 94°C for 5 min, then 35 cycles of 94°C for 30s, 57°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. Hybridisation was carried out using digoxigenin labeled internal sense strand oligonucleotide, OPG-1 (5'-ACCAAAGTGAATGCCGAG-3') under the same conditions described above. To ensure equal starting quantities of RNA in each sample, the reverse transcribed material was also amplified using oligonucleotide primers specific for rat GAPDH (39). A 414 bp fragment was amplified using a 5'-specific

- 31 -

oligonucleotide, GAPDH-4 (5'-CATGGAGAAGGCTGGGGCTC-3', representing nucleotides 306-325 of rat GAPDH) and a 3'-specific oligonucleotide, GAPDH-5 (5'-AACGGATACATTGGGGGTAG-3', representing nucleotides 701-720). Products were
5 verified with a digoxigenin-labelled internal sense strand oligonucleotide, GAPDH-1 (5'-GCTGTGGGCAAGGTCATCCC-3', representing nucleotides 640-659) using the hybridisation conditions described above.

As shown in Figure 15, OCIL mRNA was
10 constitutively expressed in fresh bone marrow cells at a high level. When cultures were stimulated by 1,25-dihydroxyvitamin D₃, a time-dependent decrease in OCIL mRNA relative to GAPDH mRNA occurred. In contrast, OPG mRNA was constitutively expressed at a low level in fresh bone
15 marrow cells, and this level was increased by treatment with 1,25-dihydroxyvitamin D₃ after 4 days. This increased mRNA level was maintained for up to 8 days culture in the presence of 1,25-dihydroxyvitamin D₃. As reported by Romas et al. (1996), in this system, multinucleate osteoclast
20 formation was observed after day 5, correlated with the decrease in OCIL mRNA expression, and an increase in mRNA for IL-11R α as well as calcitonin receptor.

PTH (1-34) or PTHrP (1-34), which influence bone resorption, have been shown to induce osteoclast formation
25 in the coculture of primary mouse calvarial osteoblasts and mouse bone marrow cells. To investigate whether PTH 1-34 regulates mRNA expression for mOCIL and the related proteins, mOCILrP1 and mOCILrP2, RT-PCR was carried out using RNA isolated from primary mouse calvarial osteoblast
30 cells which were treated with 100ng/ml hPTH-(1-34) over a time course of 0.5 to 72 hours. OCILm17 (SEQ ID NO: 16) and OCILm12 (SEQ ID NO: 14) were used as sense and antisense primers, respectively, to determine mOCIL mRNA expression. Oligonucleotides OCILm47 (SEQ ID NO: 13) and
35 OCILm12 (SEQ ID NO: 14) were used as sense and antisense primers, respectively, to determine mOCILrP1/rp2 mRNA expression. PCR and Southern blot analyses were carried

- 32 -

out under the same conditions as described above. The results showed that mOCIL mRNA expression was upregulated five-fold by PTH at 1 hour, peaking at 2 hours and returning to basal levels by 4 hours treatment: levels were
5 unchanged over the remainder of the experiment (24 hours). In contrast, mOCILrP1/rP2 mRNA was not regulated by PTH. This indicates that mOCIL is differentially regulated, while mOCILrP1 and mOCILrP2 are not.

10 Example 7: Localization of OCIL mRNA

mRNA encoding OCIL was localised in fetal, newborn and adult mouse tissues by *in situ* hybridisation using the rOCIL 402 antisense probe, using a method described previously (Katsogiannis et al, 1997 and 1998).
15 Plasmid cDNA was labelled with digoxigenin (DIG) using an RNA labelling kit (Boehringer-Mannheim, Mannheim GmbH, Germany). Hybridisation signals were detected by alkaline phosphatase staining with BCIP/NBT after incubation with an anti-digoxigenin antibody coupled to alkaline phosphatase.
20 The mRNA is expressed in a range of tissues, as summarized in Table 2.

Table 2
Adult Rat Tissues Probed with rOCIL402

| | Tissue | OCIL mRNA |
|----------|---|-----------|
| Calvaria | Osteoblasts | +++ |
| | Marrow hematopoietic cells | ++ |
| | Megakaryocytes | ++ |
| Kidney | Medulla (collecting tubules) | +++ |
| | Outer cortex (collecting tubules only) | + |
| | Glomeruli (endothelial cells only weakly positive) | -ve |
| | Proximal/distal tubules | -ve |
| Lung | pneumocytes | ++ |
| | bronchial epithelium | ++ |
| Brain | Neurones in cerebral cortex, cerebellar cortex, hippocampus; choroid plexus | +++ |
| Heart | Cardiac muscle | +++ |
| Spleen | White pulp | +++ |
| | Cortex | + |
| | Red pulp | -ve |
| Gut | Luminal epithelium | ++ |
| Liver | Hepatocytes | -ve |

- 5 *In situ* hybridization was also carried out to detect OCIL mRNA localisation in adult murine tissue and human skin, using the same method, and the results are summarized in Table 3.

Table 3
Normal Murine Tissues Expressing OCIL mRNA

| Tissues | Fetal (day 15) | Newborn (day 1) | Adult (5-8 weeks) |
|-------------------------------|-------------------|--------------------|----------------------|
| <i>Extraskeletal tissues</i> | | | |
| Brain | +++ | +++ | +++ |
| Lung | ++ | +++ | - |
| Heart | +++ | +++ | ++ |
| Kidney | ++ | +++ | - |
| (collecting tubules) | | | |
| Small Intestine | + | + | - |
| Liver | +/ (mk=+++)* | + | - |
| Skeletal muscle | +++ | +++ | ++ |
| Skin | +++ | +++ | ++ |
| Spleen | nd | nd | ++ |
| <i>Skeletal tissues/cells</i> | | | |
| Long bone | | | |
| chondrocytes | +++ | ++ | +++ |
| osteoblasts | na | +++ | +++ |
| osteoclasts | nd | ++ or - | ++ or - |
| perichondrium/ | ++ | +++ | ++ |
| periosteum | | | |
| marrow/megakaryocytes | na | ++ | ++ |
| Calvarial bone | | | |
| osteoblasts | +++ | +++ | ++ |
| osteoclasts | ++ | ++ | ++ |
| periosteum | nd | ++ | ++ |

- 5 (+) denotes weak signal
 (++) denotes moderate signal
 (+++) denotes strong signal
 (-) denotes absence of signal
 (na) not applicable

- 35 -

(nd) not determined.
*(mk) megakaryoblast of fetal liver.

OCIL mRNA localization in human skin probed with OCIL402
5 (SEQ ID NO: 4):

Epidermis (all layers) +++
**Basal layer slightly weaker signal

10 In Northern blot analyses of adult mouse tissues
using mOCIL2kb (SEQ ID NO: 10) as the probe, OCIL mRNA was
shown to be expressed in heart, skin, lung, liver, kidney,
gut and brain. In adult rat, OCIL mRNA was found to be
expressed in brain, bone, lung, liver, gut, kidney, mouse,
15 skin and heart. These results are illustrated in
Figure 16.

Since the nucleotides 900-1907 of mOCIL2kb (SEQ
ID NO: 10) were not part of the mOCIL sequence, the
Northern blot analysis was performed using mOCIL17 (SEQ ID
20 NO: 17) as probe, which detected the same 780 bp species of
mRNA. Northern blot analysis was also carried out using
plasmid containing the nucleotides 900-1907 of mOCIL2kb
(SEQ ID NO: 10) only as a probe. This probe failed to
hybridize with any mRNA.

25 Example 8: Confirmation of full length sequences
(a) Rat OCIL

A 5'-Rapid Amplification of cDNA Ends (5'-RACE)
strategy was used to obtain the 5' ends of the rOCIL cDNA,
30 using the SMART RACE cDNA Amplification Kit (Clontech,
California, USA). The antisense primer used was OCILr25
(SEQ ID NO: 32)

OCILr25 5'-CTC AGT GTT GTC TGT CCA CTT CCA AGG G-3'
35 complementary to sequences within rOCIL402 (SEQ ID NO: 4).
First-strand cDNA was synthesised from total RNA isolated

- 36 -

from hPTH 1-34 treated UMR 106 parental cells according to the manufacturer's instructions. The cDNA was further amplified by PCR using OCILr25 and UNP primer as the 5' anchored primer. The PCR conditions utilised a touchdown

5 PCR protocol with denaturation at 94°C for 1 min, then 5 cycles at 94°C for 30 sec, 72°C for 1 min, and then 5 cycles of 94°C for 30 sec, 70°C for 30 sec and 72°C for 1 min, followed by 50 cycles of 94°C for 30 s, 65°C for 30s, and 72°C for 1 min. An extension of 398 bp of 5'- sequence

10 of rOCIL1.3kb (SEQ ID NO: 7) was obtained. The full length rat OCIL sequence is 1628 bp, designated rOCIL (SEQ ID NO: 33). Figure 17 summarises the sequence of 402 (SEQ ID NO: 4), rOCIL1.3 (SEQ ID NO:7), rOCIL323 and rOCIL (SEQ ID NO: 33).

15

(b) *Mouse OCIL*

A 5'-RACE strategy was used to confirm the mOCIL2kb sequence. The antisense primers used were OCILr25 (SEQ ID NO: 32), which was 100% identical to mOCIL2kb (SEQ

20 ID NO: 10), and a specific primer OCILm75 (SEQ ID NO: 34).

OCILm75: 5'-CAG TTT TGC GGG CAA GCA GCA TAG-3'

complementary to sequences within mOCIL2kb (SEQ ID NO: 10).

25 First-strand cDNA was synthesised from total RNA isolated from mouse spleen cells according to the manufacturer's instructions. The cDNA was further amplified by PCR using OCILr25 or OCILm75 and UNP as the 5' anchored primer, in a touchdown PCR protocol with denaturation at 94°C for 1 min,

30 then 5 cycles at 94°C for 30 sec, 72°C for 1 min, and then 5 cycles of 94°C for 30 sec, 70°C for 30 sec and 72°C for 1 min, followed by 40 cycles of 94°C for 30 s, 65°C for 30s, and 72°C for 1 min.

A 3'-RACE strategy was also used to obtain the 3'

35 ends of the mOCIL cDNA. The sense specific primer used was OCILm76 (SEQ ID NO: 35).

- 37 -

OCILm76 5'-AGG CAG CCC GCA GGA GGT AGA AG-3'

complementary to sequences within mOCIL2kb (SEQ ID NO: 10). First-strand cDNA was synthesised from total RNA isolated
5 from mouse spleen cells according to the manufacturer's instructions. The cDNA was further amplified by PCR using OCILm76 and UNP primer as the 3' anchored primer in a touchdown PCR protocol with denaturation at 94°C for 1 min, then 5 cycles at 94°C for 30 sec, 72°C for 1 min, and then
10 5 cycles of 94°C 30 sec, 70°C for 30 sec and 72°C for 1 min, followed by 30 cycles of 94°C for 30 s, 65°C for 30s, and 72°C for 1 min.

A full length mOCIL cDNA sequence of 1206 bp was obtained and designated mOCIL (SEQ ID NO: 36). This
15 sequence confirmed that nucleotides 1-320 of the original mOCIL2kb represented an inverted repeat of the 3' end of the sequence, and that nucleotides 900-1907 of mOCIL2kb were not part of the mOCIL sequence.

20 (c) *Human OCIL*

A 5'-RACE strategy was used to confirm the hOCIL sequence. The specific antisense primer used was OCILh1 (SEQ ID NO: 43),

25 OCILh1: 5'-CTC TGC TCA GCC CAA TCC AGT GAT CAG-3'

complementary to sequences within hOCIL clone 1 (SEQ ID NO: 20). According to the manufacturer's instructions, first-strand cDNA was synthesised using human placental total
30 RNA, which is included in the SMART RACE cDNA Amplification Kit (Clontech, California, USA). The cDNA was further amplified by PCR using OCILh1 and UNP primer as the 5' anchored primer using a touchdown PCR protocol with denaturation at 94°C for 1 min, then 5 cycles at 94°C for
35 30 sec, 72°C for 1 min, and then 5 cycles of 94°C for 30 sec, 70°C for 30 sec and 72°C for 1 min, followed by 50 cycles of 94°C for 30 s, 65°C for 30s, and 72°C for 1 min.

- 38 -

Three different 5' end sequences were obtained, designated hOCIL clone 2 (SEQ ID NO: 44), hOCIL clone 3 (SEQ ID NO: 45) and hOCIL clone 4 (SEQ ID NO: 46).

The length of hOCIL clone 2 (SEQ ID NO: 44),
5 hOCIL clone 3 (SEQ ID NO: 45) and hOCIL clone 4 (SEQ ID NO: 46) is 820, 937 and 845 bp, respectively. Minor differences in the nucleotide sequences were noted between hOCIL clones 1, 2, 3 and 4. These were:

- 1) At position 545 in human OCIL clone 1 a "C" was called and a "C" was at this equivalent position in clones 2 and 3, whilst in clone 4 (at position 117), a "G" was called.
- 2) At position 649 in human OCIL clone 1 a "T" was called, and a "T" was called at this position in human OCIL
15 clone 4, whilst a "C" was called in the equivalent positions for clones 2 (at position 164) and 3 (at position 189).
- 3) At position 835 in human OCIL clone 1 and at equivalent positions for hOCIL clones 2 and 3, a "G" was
20 called, whilst at an equivalent position for human OCIL clone 4 (at position 467), an "A" was called.

Of these clones, only hOCIL clone 3 predicted a protein sequence, while hOCIL clones 1, 2 and 4 did not possess a Kozak sequence predicting an initiating
25 methionine residue. Analysis of the genomic structure of human OCIL (below) predicts that hOCIL clones 1 and 2 result from read-through into intron II, and therefore, represent prespliced mRNA species (Figure 18a). hOCIL clone 4 appears to represent an alternatively spliced mRNA
30 transcript that does not encode a full length protein. hOCIL clone 3 predicts a protein of 191 amino acids which is a C-lectin type II membrane-bound protein. The protein is predicted to have an intracellular domain of 30 amino acids, transmembrane domain of 29 amino acids and an
35 extracellular domain of 132 amino acids. Within the extracellular domain is a C-lectin domain of 112 amino acids (amino acids 75 to 186; Figure 18b). The sequence

- 39 -

from 13 bp to 845 bp of hOCIL clone 3 is identical to that from 7 bp to 850 bp of LLT1, a cDNA of 850 bp encoding a C-type lectin expressed by Natural Killer (NK) cells, T cells, and B cells (GenBank database Accession No.

- 5 AF133299). The features of hOCIL clone 3 identify this as encoding the human equivalent of mouse and rat OCIL.

The hOCIL gene is 46.5kb in length (SEQ ID NO: 21). The hOCIL gene is composed of 6 exons, and may be alternatively spliced at the 5' end, as illustrated in

10 Figure 18a. hOCIL clone 1 (SEQ ID NO: 20), as well as hOCIL clone 2 (SEQ ID NO: 44) contains exons III, IV, V and VI. hOCIL clone 3 (SEQ ID NO: 45) contains exons II, III, IV, V and VI. hOCIL clone 4 (SEQ ID NO: 46) contains exons I, III, IV, V and VI.

- 15 A 3-RACE strategy was also used to obtain the 3' ends of the cDNA using the SMART RACE cDNA Amplification Kit (Clontech, California, USA). The sense specific primer used was OCILh3'-1 (SEQ ID NO: 47)

20 OCILh3'-1 5'-GCTGATCTTGCTCAGGTGAAAGCTTCC-3'

- complementary to sequences within hOCIL (SEQ ID NO: 20). First-strand cDNA was synthesised from total RNA isolated from MG63 cells, a human osteosarcoma cell line, according
- 25 to the manufacturer's instructions. The cDNA was further amplified by PCR using OCILh3'-1 and UNP primer as the 3' anchored primer. The PCR conditions utilised a touchdown PCR protocol with denaturation at 94°C for 1 min, then 5 cycles at 94°C for 30 sec, 72°C for 1 min, and then 5
- 30 cycles of 94°C 30 sec, 70°C for 30 sec and 72°C for 1 min, followed by 30 cycles of 94°C for 30 s, 65°C for 30s, and 72°C for 1 min.

3' RACE confirmed the 3' end sequence of the hOCIL clones.

35

- 40 -

Example 9: Antibodies Directed Against OCIL

The following peptide fragment of the deduced amino acid sequence derived from the cDNA sequence of mOCIL17 (SEQ ID NO: 17) was synthesized, and was used to immunize rabbits, using standard protocols.

H-Cys-Met-Ala-Gln-Glu-Ala-Gln-Leu-Ala-Arg-Phe-Asp-Asn-Gln-Asp-Glu-Leu-Asn-Phe-OH (SEQ ID NO: 26)

This peptide sequence showed a high homology to mOCILrP1 (SEQ ID NO: 41) and mOCILrP2 (SEQ ID NO: 42), as follows:

```

1      CMAQE AQLARFDNQDELN
      |||||
15 108 CMAQE AQLARFDNQDELN    mOCIL (SEQ ID NO: 40)

1      CMAQE AQLARFDNQDELN
      |||||
120 CMAQE AQLARFDNEKELN    mOCILrP1 (SEQ ID NO: 41)

20 1      CMAQE AQLARFDNQDELN
      |||||
120 CMAQE AQLARFDNEEELI    mOCILrP2 (SEQ ID NO: 42)

```

Two specific peptide fragments of the deduced amino acid sequence derived from the cDNA sequence of mOCIL (SEQ ID NO: 36) and mOCILrP1/mOCILrP2 (SEQ ID NO: 12 and 15) in the intracellular domain were synthesised, and were also used to raise antibodies:

Antibody MOCIL-3 is specific for an epitope in the following sequence of mOCIL:

H-Cys-Val-Thr-Lys-Ala-Ser-Leu-Pro-Met-Leu-Ser-Pro-Thr-Gly-Ser-Pro-Gln-Glu-NH₂ (SEQ ID NO: 48)

35

- 41 -

Antibody MOCIL-RP-1 is specific for an epitope in the following sequence of mOCILrP1/mOCILrP2:

H-Cys-Val-Gln-Lys-Pro-Glu-Glu-Gly-asn-Gly-Pro-Leu-Gly-Thr-Gly-Asp-NH₂ (SEQ ID NO: 49)

5

The antibodies raised may be used to detect the OCIL protein, using standard immunohistochemical methods, or to neutralize OCIL activity in murine co-cultures to stimulate osteoclast formation.

10

Example 10: Immunohistochemistry

Rabbit polyclonal antibodies prepared as described in Example 7 were used for immunohistochemistry. A kit for the standard peroxidase-labelled streptavidin-biotin detection method (DAKO, Boenisch, 1989) was used according to the manufacturer's instructions, with minor modifications. The dilution of the antiserum used was optimised in preliminary experiments. Incubation of tissue sections with a 1:100 dilution of the primary antiserum was carried out overnight at 4°C in a humidified chamber. Peroxidase activity was detected with 3'-3'-diaminobenzidine tetrahydrochloride (Sigma) and 0.15% H₂O₂. Slides were counterstained with haematoxylin, dehydrated and mounted on a coverslip. The tissue expression of mOCIL, mOCILrP1 and mOCILrP2 proteins as detected using the 3 antibodies raised against the sequences SEQ ID NO: 26; SEQ ID NO: 48 and SEQ ID NO: 49 was identical. The results are summarized in Table 4.

25

Table 4

Normal Murine Tissues Expressing mOCIL or mOCILrP protein

| Tissues | Fetal (day 15) | Newborn (day 1) | Adult (5-8 weeks) |
|-------------------------------|-------------------|--------------------|----------------------|
| <i>Extraskeletal tissues</i> | | | |
| Brain | nd | + | +++ |
| Lung | nd | ++ | + |
| Heart | nd | ++ | ++ |
| Kidney | nd | ++ | ++ |
| (collecting tubules) | | | |
| Small Intestine | nd | nd | nd |
| Liver | nd | nd | nd |
| Skeletal muscle | nd | ++ | ++ |
| Skin | nd | ++ | ++ |
| Spleen | nd | nd | nd |
| <i>Skeletal tissues/cells</i> | | | |
| Long bone | | | |
| chondrocytes | nd | ++ | ++ |
| osteoblasts | na | +++ | +++ |
| osteoclasts | nd | nd | nd |
| perichondrium/periosteum | nd | ++ | ++ |
| marrow/megakaryocytes | na | ++ | ++ |

- 5 (+) denotes weak signal;
 (++) denotes moderate signal;
 (+++) denotes strong signal;
 (-) denotes absence of signal;
 (na) not applicable;
 10 (nd) not determined.

- 43 -

Example 11: Production of Recombinant OCIL protein in a mammalian expression system

OCIL proteins were prepared by recombinant DNA technology to allow more extensive laboratory studies of their actions on osteoclast formation as well as osteoblast function. Soluble mouse and rat OCIL cDNA tagged at the N-terminus with the FLAG epitope were constructed in the pEF-BOS Mammalian expression vector (Mizushima & Nagata 1990), which had been modified to contain an in-frame IL-3 signal sequence and FLAG peptide coding sequence (gift of Dr. D Hilton).

In order to obtain a RT-PCR product encoding the mOCIL (SEQ ID NO: 36) extracellular domain (amino acids 63-207) to clone into the MluI site of the vector, as shown in Figure 19a, the RT-PCR was carried out using total RNA isolated from primary mouse calvarial osteoblasts, which support osteoclast differentiation in coculture. A sense primer, OCILm33, comprising OCILm32 representing nucleotides 245-269 of mOCIL (SEQ ID NO: 36) and containing a MluI site, designated primer OCILm33 (SEQ ID NO: 27):

OCILm33 5'-GCC ACG CGT TTG TCA GCA ACA AAG ACA GAA CAG-3'

and an antisense primer representing nucleotides 746-725 of mOCIL (SEQ ID NO: 36) and containing a MluI site, designated primer OCILm46 (SEQ ID NO: 28),

OCILm46 5'-GCC ACG CGT GGG ACC ATA GGG GAA AAA GTA G-3'

were used as primers in the PCR. PCR was run at 94°C for 5 min, then 35 cycles of 94°C for 30 s, 60°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. A 501 bp fragment was obtained and further cloned into the expression vector pEF-BOS. The open reading frame and FLAG fusion was confirmed by sequencing (bp 1-132), and the 501 bp fragment sequence (SEQ ID NO: 29) was confirmed to be identical to mOCIL17 (SEQ ID NO: 17). The

- 44 -

sequencing results also showed that the primer OCILm46 had 22 of 23 bp complementary to mOCIL17 (SEQ ID NO: 17) and mOCIL (SEQ ID NO: 36):

```

5  5'-GCCACGCGTGGGACCATAGGGGAAAAAGTAG-3' Primer OCILm46
      ||||||||||||||| |||||
3'-ATCGTGAAACCTGGTATCCCTTTCTCATC-5' mOCIL (725) Strand +

```

To obtain a PCR product encoding the rOCIL1.3kb (SEQ ID NO: 7) extracellular domain (amino acids 40-179), a sense primer to represent nucleotides 126-146 of rOCIL1.3kb with the MluI site, designated primer OCILr22 (SEQ ID NO: 30),

```

15  OCILr22  5'- GCC ACG CGT TCA GTA AAA AAG ACA GCC AAG-3'

```

and an antisense primer representing nucleotides 544-526 of rOCIL1.3kb with the MluI site, and designated primer OCILr23 (SEQ ID NO: 31),

```

20  OCILr23  5'-GCC CAG CGT AAC TAC AGG CAC TGT GAG G-3'

```

were used as primers in a PCR. PCR was carried using rOCIL1.3 kb plasmid as a template and run at 94°C for 5 min, then 35 cycles of 94°C for 30 s, 60°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. A 421 bp fragment was obtained and cloned into the expression vector pEF-BOS, as shown in Figure 19b. The open reading frame and FLAG fusion were confirmed by

```

30  sequencing.

```

HEK 293 cells were transfected with both mouse and rat expression constructs using Lipofectamine (Life Technologies, Inc). Supernatant was harvested after 72 hours. The recombinant protein was purified by

```

35  incubation with the anti-FLAG M2 affinity gel (Kodak), and
    eluted with the FLAG peptide (Kodak) as outlined in the
    manufacturer's protocol. The purified protein was used to

```

- 45 -

study its effects on osteoclast formation in murine cocultures.

An experiment was also carried out to determine the action of rOCIL protein in osteoclast formation.

- 5 Primary mouse calvarial osteoblasts were cocultured with spleen or bone marrow cells obtained from 6 week-old mice and stimulated with 1,25-dihydroxyvitamin D₃ and PGE₂ in the presence of rOCIL or mOCIL protein (15 ng/ml) for 10 days. A negative control was carried out with carrier
10 buffer alone. As shown in Figure 20, both rOCIL protein (Figure 20a) and mOCIL protein (Figure 20b) significantly reduced the number of osteoclasts formed when compared to the presence of carrier buffer alone.

15 Example 12: Effect of mOCIL Protein on Osteoclast Formation

To determine the action of mOCIL protein on osteoclast formation, mouse spleen cells were obtained from 6-week old mice and cultured in medium containing 10% FCS,
20 25ng/ml hM-CSF and 50ng/ml murine soluble RANKL in the absence or presence of mOCIL protein at a concentration of 12.5 ng/ml. mOCIL protein treatment resulted in a 60% inhibition of sRANKL and hM-CSF stimulated osteoclast formation, as illustrated in Figure 21.

25 Example 13: Production of Recombinant OCIL protein in an E.coli expression system

- In order to increase the expression level for mOCIL protein, an *E.coli* expression system was used. A DNA
30 fragment encoding the extracellular domain (residues 76-207) of mOCIL was obtained by PCR and cloned into the *EcoRI* and *HindIII* site of pMAL-c2 (New England Biolabs Inc.), creating a gene fusion with the MBP (maltose binding protein)-encoding *male* gene. PCR was performed using a
35 plasmid which contained mOCIL17 cDNA sequence (SEQ ID NO: 17) as a template. The reaction used a sense primer representing nucleotides 285-303 of mOCIL (SEQ ID NO: 36)

- 46 -

encoding amino acids 76-81, TYAACP, in SEQ ID NO: 39 with an *EcoRI* site, designated primer OCILm65 (SEQ ID NO: 50),

OCILm65 5'-TCAGAATTACCTATGCTGCTTGCCCGC-3'

5

and an antisense primer representing nucleotides 711-690 of mOCIL after the stop codon in SEQ ID NO: 36 with a *HindIII* site, and designated primer OCILm66 (SEQ ID NO: 51):

10 OCILm66 5'-GGTTAAGCTTCAGGCTAAAAAGCGTCTCTTG-3'.

PCR was run at 94°C for 5 min, then 30 cycles of 94°C for 30 s, 60°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. The PCR product was
15 then digested with *EcoRI* and *HindIII*, and cloned into pMAL-c2, as shown in Figure 22. The open reading frame and MBP fusion were confirmed by sequencing.

Example 14: Recombinant mOCIL-related protein constructs

20 To determine whether mOCIL-related proteins also have an inhibitory effect on osteoclast formation, the sequences encoding the extracellular domains of mOCILrP1 and mOCILrP2 were also inserted into the *EcoRI* and *HindIII* sites of pMAL-c2 (New England Biolabs Inc.), as described
25 above.

PCR was performed using a plasmid which contained mOCILrP1 cDNA sequence (SEQ ID NO: 12) as a template. A sense primer representing nucleotides 283-302 of mOCILrP1 (SEQ ID NO: 12) encoding amino acids 88-93, TYAACP, in SEQ
30 ID NO: 40 with an *EcoRI* site, designated primer OCILm88 (SEQ ID NO: 52),

OCILm88 5'-TCAGAATTACCTATGCTGCTTGCCCGAA-3'

35 and an antisense primer representing nucleotides 742-720 of mOCILrP1 (SEQ ID NO: 12) and 739-717 of mOCILrP2 (SEQ ID NO: 15), with a *HindIII* site, and designated primer OCILm87

- 47 -

(SEQ ID NO: 53)

OCILm87 5'-GGTTAAGCTTGGGACCATAGGGGAAAAAGTAG-3'

5 were constructed. PCR was run at 94°C for 5 min, then 30 cycles of 94°C for 30 s, 60°C for 30s, and 72°C for 1 min, followed by a final extension step of 72°C for 10 min. The PCR product was then digested with *EcoRI* and *HindIII* and cloned into pMAL-c2 (Figure 23). The open reading frame
10 and MBP fusion were confirmed by sequencing.

For the mOCILrP2 construct, PCR was performed using a plasmid which contained mOCILrP2 cDNA sequence (SEQ ID NO: 15) as a template. A sense primer, representing nucleotides 283-302 of mOCILrP2 (SEQ ID NO: 15) encoding
15 amino acids 88-93, TYAACS of SEQ ID NO: 41 with an *EcoRI* site, designated primer OCILm89 (SEQ ID NO: 54),

OCILm89 5'-TCAGAAATTCACCTATGCTGCTTGCTCAA-3'

20 and antisense primer OCILm87 (SEQ ID NO: 53) were used for PCR. PCR and cloning procedures were carried out under the same conditions as above, as shown in Figure 24.

Example 15: Recombinant hOCIL protein construct

25 A recombinant hOCIL protein construct was also made using the same system. A sense primer, representing nucleotides 694-711 of hOCIL clone 1 (SEQ ID NO: 20) with an *EcoRI* site, designated primer hpMAL-1 (SEQ ID NO: 55),

30 hpMAL-1 5'-GCGGAATTCCTTCAAGCTGCATGCCC-3'

and an antisense primer representing nucleotides 1034-1055 of hOCIL clone 1 (SEQ ID NO: 20) with a *BamHI* site, and designated primer hpMAL-2 (SEQ ID NO: 56)

35

hpMAL-2 5'-CCTGGGATCCGCTTTGCTGTAACATCTAGAC-3'

- 48 -

were used to run PCR under the same conditions as above. The PCR product was then digested with *EcoRI* and *BamHI*, and cloned into pMAL-c2. The open reading frame and MBP fusion was confirmed by sequencing, as shown in Figure 25.

5

Example 16: Expression and purification of mOCILrP and hOCIL

Competent strain BL21 *E.coli* cells were transformed with the constructs produced in the preceding two examples, and the corresponding fusion protein was induced with IPTG (isopropyl-1-thio- β -D-galactopyranoside) according to the manufacturer's instructions. The MBP-OCIL fusion protein was isolated from the soluble bacterial fraction using affinity chromatography as outlined in the manufacturer's instructions. The eluant fractions were subjected to SDS-PAGE, and transferred to membranes [PVDF (polyvinylidene difluoride) Western blotting membranes (Roche Molecular Biochemicals)]. Western blot analyses were performed with a rabbit anti-MBP serum (New England Biolabs Inc.) and a BM chemiluminescence blotting substrate (POD) detection system (Roche Molecular Biochemicals). Fractions containing the MBP-OCIL fusion protein were pooled and concentrated using an Amicon ultrafiltration YM10 membrane (Millipore, Bedford, MA). The protein concentration was ascertained in a BCA protein assay (Pierce). The estimated yield of MBP-mOCIL ranged between 0.1-0.4 mg/L.

Example 17: Inhibition of osteoclast formation

Experiments were carried out to determine the action of MBP fusion OCIL proteins on osteoclast formation. *Mouse culture system*

Mouse spleen cells obtained from 6 week old adult mice were cultured in medium containing 10% FCS and 25ng/ml M-CSF and 50ng/ml sRANKL in the absence or presence of MBP or MBP-mOCIL fusion protein at various concentrations. After 7 days, cells were fixed and subjected to TRAP

35

- 49 -

staining. As shown in Figure 26a, MBP-mOCIL fusion protein significantly reduced the number of osteoclasts formed when compared to MBP protein alone, and this effect was shown in a dose-dependent manner.

5 It has been reported that IL-18 inhibits osteoclast formation mediated by T cells (Horwood et al., 1998). To further investigate whether the mOCIL inhibition of osteoclast formation is a T cell-dependent effect, T cell-depleted mouse spleen cell cultures were carried out
10 as reported by Horwood et al., (1998). T cells were depleted with CD3 antibody from spleen cells and the remaining cells were cultured in medium containing 10% FCS, 25ng/ml M-CSF and 50ng/ml sRANKL in the absence or presence of MBP or MBP-mOCIL fusion protein at a concentration of
15 500ng/ml. The results, summarised in Figure 26b, showed that mOCIL inhibited osteoclast formation, implying that its actions were T-cell independent.

The effect of MBP-mOCILrP1 and MBP-mOCILrP2 fusion protein on osteoclast formation was also examined in
20 the T-cell depleted mouse spleen cell culture system. The results are shown in Figure 27. Both MBP-mOCILrP1 (Figure 27a) and MBP-mOCILrP2 fusion proteins (Figure 27b), like mOCIL, inhibited osteoclast formation in a T cell independent fashion.

25 *Human monocyte culture*

Monocyte cultures were prepared as described by Quinn et al., (1998). Monocytes were isolated from the peripheral blood of normal healthy subjects. Human PBMCs were prepared from diluted blood (1:1 in Hanks Balanced
30 Salt Solution (HBSS; Life Technologies, Grand Island, NY) which was layered over Ficoll-Paque® solution (Pharmacia Biotech, Uppsala, Sweden), centrifuged (693g), then washed and resuspended in MEM medium containing 10% FCS. Monocyte cultures were prepared by adding 10⁶ PBMCs to 6mm diameter
35 culture wells containing bovine cortical bone slices in MEM medium containing 10% FCS; after 1 hour, coverslips and bone slices were removed, vigorously rinsed to remove non-

- 50 -

adherent cells, and placed in 10mm diameter culture wells. Monocyte cultures were maintained in these culture wells in 0.4ml MEM medium containing 10% FCS, recombinant human M-CSF (25ng/ml) and recombinant human sRANKL (30 ng/ml) in the absence or presence of MBP (500 ng/ml) or MBP-hOCIL (500ng/ml) fusion protein for 21 days. Medium and added factors were entirely replaced every 3 days. After 21 days, bone slices were removed for TRAP staining and bone resorption pit analysis. The multinucleate osteoclasts were counted, and the results are shown in Table 5. Human OCIL inhibited osteoclast formation from human monocytic cells.

Table 5
Effects of MBP-hOCIL fusion protein on osteoclast formation in human monocyte cultures

| Well | Control (RANKL+M-CSF) | MBP (500 ng/ml) | MBP-hOCIL (500 ng/ml) |
|----------------|-----------------------|-----------------|-----------------------|
| 1 | 205 | 40 | 6 |
| 2 | 146 | 180 | 16 |
| 3 | 37 | 17 | 34 |
| 4 | 66 | 42 | 9 |
| 5 | 66 | 22 | 73 |
| 6 | 71 | 63 | 14 |
| 7 | 38 | 54 | 20 |
| 8 | 25 | 29 | 34 |
| Mean \pm SEM | 81.7 \pm 22.0 | 55.9 \pm 18.6 | 26.12 \pm 7.62 |

DISCUSSION

We conclude that in osteoblasts OCIL and OCIL related proteins are expressed on the cell surface as type II membrane peptides. Contact with haematopoietic precursor cells prevents further differentiation into mononucleate osteoclast precursors, and ultimately into functional multinucleate osteoclasts.

Without wishing to limit the scope of the invention by any proposed mechanism, we consider that upregulation of OCIL mRNA expression by the same osteotropic factors that increase expression of RANKL is consistent with the hypothesis that regulation of bone resorption by osteoclasts is tightly regulated. According to this hypothesis, stimulation of multinucleate osteoclast formation through RANKL would simultaneously prevent the generation of new osteoclasts through the action of OCIL. If this system is operative under normal physiological conditions, then bone resorption becomes a self-limiting process.

Notwithstanding the above, mOCILrP1 and mOCILrP2 are not regulated by osteotropic agents that regulate mOCIL, but like mOCIL, both mOCILrP1 and mOCILrP2 have the capacity to inhibit osteoclast formation. Thus each of the three polypeptides, mOCIL, mOCILrP1 and mOCILrP2 is equally useful for therapy to limit osteoclast formation or to promote osteoclast formation through blockade of their actions. Given the degree of homology between these molecules, each may substitute for one another. However, each can be distinguished by several criteria. These include:

(a) Nucleotide sequence: mOCIL, mOCILrP1 and mOCILrP2 appear to be derived from a common ancestral gene; however, there are nucleotide differences which permit identification of the three molecules using specific oligonucleotide primers in RT-PCR.

(b) Gene structure: The promoter of mOCIL is a TATA promoter, while the promoter for mOCILrP1 is a GC-rich

- 53 -

region containing an SP 1 binding site.

(c) The expression of mOCIL is regulated by PTH, while the expression of mOCILrP1 and mOCILrP2 is not.

(d) The polypeptide products of mOCIL, mOCILrP1
5 and mOCILrP2 can be distinguished using antibodies directed against peptide fragments of mOCIL and mOCILrP1/rP2 based on the intracellular domains of the respective proteins.

In vivo, OCIL and OCILrP have the potential to be used as therapeutic agents in the treatment of conditions
10 which are characterised by excessive bone resorption, such as osteoporosis, primary hyperparathyroidism, Paget's disease, rheumatoid arthritis, renal osteodystrophy, and humoral hypercalcaemia of malignancy, as well as metastatic bone disease. Modulation of the expression or function of
15 the factor may also be useful in the treatment of disorders involving extra-skeletal calcification.

It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding,
20 various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.

References cited herein are listed on the
25 following pages, and are incorporated herein by this reference.

REFERENCES

- Anderson, D.M., Maraskovsky, E., Billingsley, W.L.,
Dougall, W.C., Tometsko, M.E., Roux, E.R., Teepe, M.C.,
5 DuBose, R.F., Cosman, D. and Gaiibert, L.
Nature, 1997 390 175-179.
- Boenisch, T.
In: Naish, S.J., Ed Handbook: Immunochemical Staining
10 Methods. DAKOPATTS (DAKO Corporation): CA; 1989 16-17.
- Chomczynski, P. and Sacchi, N.
Anal Biochem, 1987 162 156-159.
- 15 Ganius, H.J.
Eur. U. Biochem., 1997 243 543-576.
- Horwood et al, 1998a
Endocrinology, 1998 139 4743-4746
20 Horwood et al., 1998b,
J.Clin. Invest, 1998 101 595-603.
- Ikegame et al.,
25 J.Bone Miner. Res., 1995 10 59-65
- Kartsogiannis, V., Moseley, J., McKelvie, B., Chou, S.T.,
Hards, D.K., Ng, K.W., Martin, T.J. and Zhou, H.
Bone, 1998 22 189-194.
30 Kartsogiannis, V., Udagawa, N., Ng, K.W., Martin, T.J.,
Moseley, J. and Zhou, H.
Bone, 1997 21 385-392.
- 35 Kieda, C.
Adv. Exp. Med. Biol., 1998 435 75-82.

- 55 -

- Martin, T.J., Moseley, J.M. and Gillespie, M.T.
Critical Reviews in Biochemistry and Molecular Biology,
1991 26 377-395.
- 5 Martin, T.J. and Udagawa, N.
Trends in Endocrinology and Metabolism, 1998 9 6-12.
- Mizhashi, N., and Nagata, S.
Nucleic Acids Res., 1990 18 5322
- 10 Ng, K.W., Gummer, P.R., Michelangeli, V.P., Bateman, W.,
Mascara, T., Cole, W.G. and Martin, T.J.
J Bone Miner Res, 1988 3 53-61.
- 15 Quinn, J.M.W., Elliott, J., Gillespie, M.T. and Martin,
T.J. (1998). A combination of osteoclast differentiating
factor and macrophage-colony stimulating factor is
sufficient for both human and mouse osteoclast formation in
vitro. *Endocrinology*. 139, 4424-4427.
- 20 Romas et al.
J.Exp. Med., 1996 183 2581-2591.
- Sambrook, J., Fritsch, E.F. and Maniatis, T.
- 25 Molecular Cloning - A Laboratory Manual, Second Edition,
Cold Spring Harbor Laboratory Press, 1989.
- Sharon, N. and Lis, H.
Essays Biochem., 1995 30 59-75.
- 30

- Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelly, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Trail, G.,
5 Sullivan, J., Davy, E., Bucay, N., Renshaw-Geee, L., Hughes, T.M., Hill, D., Pattison, W., Campbell, P., Boyle, W.J. *et al*
Cell, 1997 89 309-319.
- 10 Suda, T., Udagawa, N., Nakamura, I., Miyaura, C. and Takahishi, N.
Bone, 1995 17 87S-91S.
- Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie,
15 M.T. and Martin, T.J.
Endocrine Reviews, 1999 20 345-357.
- Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J.M., Martin, T.J. and Suda, T.
20 Endocrinology, 1988 123 2600-2602.
- Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T. and Higashio, K.
Biochem. Biophys. Res. Commun., 1997 234 137-142.
- 25 Wong, B.R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E. and Barlett, F.S.
3rd, Frankel WN, Lee SY and Choi Y.
J. Biol. Chem., 1997 272 25190-25194.
- 30 Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinoshita, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T.
35 Proc. Natl. Acad. Sci. USA, [1998] 95 3597-3602.

Zhou H., et al

J. Biol.Chem., 269 22433-22439.

CLAIMS

1. An isolated nucleic acid molecule which comprises a sequence encoding a type II membrane polypeptide expressed on the osteoblast cell surface, selected from the group consisting of osteoclast inhibitory lectin (OCIL) and OCIL-related protein, which
 - a) is expressed at least on osteoblasts, and
 - b) inhibits osteoclast differentiation from haematopoietic cell precursors.
2. A nucleic acid molecule according to claim 1, which is a cDNA.
3. A nucleic acid molecule according to claim 1 or claim 2, which is of human, mouse or rat origin.
4. A nucleic acid molecule according to claim 2, in which the cDNA comprises a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 36, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.
5. A nucleic acid molecule according to claim 1, which is a gDNA.
6. A nucleic acid molecule according to claim 5, in which the gDNA comprises a sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 21, and SEQ ID NO: 37, or which hybridises to said nucleic acid molecule under stringent conditions.
7. A nucleic acid molecule according to any one of claims 1 to 6, which encodes an extracellular domain of an OCIL or of an OCIL-related protein.
8. A nucleic acid molecule according to any one of claims 1 to 7, which encodes a protein which inhibits differentiation of haematopoietic stem cells to osteoclast progenitor cells.
9. A nucleic acid molecule according to any one of claims 1 to 8, which comprises a 110 base pair sequence as set out in SEQ ID NO: 2.

10. An anti-sense sequence directed against a nucleic acid molecule according to any one of claims 1 to 9.
11. An anti-sense sequence according to claim 10, directed against SEQ ID NO: 10.
- 5 12. An anti-sense sequence according to claim 10 or claim 11, which is SEQ ID NO: 24 or SEQ ID NO: 25.
13. An isolated polypeptide encoded by a nucleic acid molecule according to any one of claims 1 to 9.
14. A polypeptide according to claim 13, which is
10 encoded by the human cDNA or gDNA sequence.
15. A polypeptide according to claim 13, which is encoded by the mouse cDNA or gDNA sequence.
16. A polypeptide according to claim 15, comprising a sequence selected from the group consisting of SEQ ID
15 NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42.
17. A polypeptide according to claim 13, which comprises an amino acid sequence encoded by SEQ ID NO: 20.
18. An isolated polypeptide selected from the group consisting of a C-lectin motif, an extracellular domain, a
20 transmembrane domain, or a cytoplasmic domain of a polypeptide according to any one of claims 13 to 17.
19. An antibody directed against a polypeptide according to any one of claims 13 to 18.
20. An antibody according to claim 19, which is
25 directed against an epitope present in a sequence selected from the group consisting of
H-Cys-Met-Ala-Gln-Glu-Ala-Gln-Leu-Ala-Arg-Phe-Asp-Asn-Gln-Asp-Glu-Leu-Asn-Phe-OH (SEQ ID NO: 26).
H-Cys-Val-Thr-Lys-Ala-Ser-Leu-Pro-Met-Leu-Ser-Pro-Thr- Gly-
30 Ser-Pro-Gln-Glu-NH₂ (SEQ ID NO: 48), and
H-Cys-Val-Gln-Lys-Pro-Glu-Glu-Gly-asn-Gly-Pro-Leu-Gly-Thr-Gly-Asp-NH₂ (SEQ ID NO: 49).
21. An antibody according to claim 19 or claim 20, which is monoclonal.
- 35 22. A composition comprising a polypeptide according to any one of claims 13 to 18, together with a pharmaceutically-acceptable carrier.

23. A composition comprising an antibody according to any one of claims 19 to 21, together with a pharmaceutically-acceptable carrier.
24. A method of treatment of a condition
- 5 characterised by abnormal bone resorption, comprising the step of administering an effective amount of a modulator of expression or function of a polypeptide according to any one of claims 13 to 18.
25. A method according to claim 24, in which the
- 10 condition involves excessive bone resorption, and the method comprises administration of a polypeptide according to any one of claims 13 to 18, or a nucleic acid encoding this polypeptide, or encoding a biologically-active fragment or analogue thereof.
- 15 26. A method according to claim 25, in which the condition is selected from the group consisting of osteoporosis, primary hyperparathyroidism, Paget's disease, rheumatoid arthritis, renal osteodystrophy, humoral hypercalcaemia of malignancy, and conditions where cancer
- 20 has metastasised to bone.
27. A method according to claim 24, in which the condition involves deficient bone resorption, and the method comprises administration of an antibody according to any one of claims 19 to 21 or an anti-sense oligonucleotide
- 25 according to any one of claims 10 to 12.
28. A method according to claim 26, in which the condition is osteopetrosis.
29. A method of promoting healing of bone fractures, particularly in an individual in whom fracture healing is
- 30 delayed or deficient, comprising the step of administering an effective amount of a polypeptide according to any one of claims 13 to 18.
30. A method according to claim 29, in which the individual is suffering from osteoporosis or diabetes
- 35 mellitus.
31. A method of modulating breast and/or lymph node development, comprising the step of administering an

- 61 -

effective amount of a modulator of expression or function of a polypeptide according to any one of claims 13 to 18 to a subject in need of such treatment.

32. A diagnostic kit for detection of abnormalities
- 5 in the structure, expression or control of a type II membrane polypeptide expressed on the osteoblast cell surface, selected from the group consisting of osteoclast inhibitory lectin (OCIL) and OCIL-related protein, comprising a reagent selected from the group consisting of
- 10 (a) a nucleic acid according to any one of claims 1 to 9, or a fragment thereof capable of hybridising to a nucleic acid according to any one of claims 1 to 9;
- (b) an anti-sense nucleic acid according to any one
- 15 of claims 10 to 12;
- (c) a polypeptide according to any one of claims 13 to 18, and
- (d) an antibody according to any one of claims 19 to 21.
- 20 33. A diagnostic kit according to claim 32, in which the reagent is labelled with a detectable marker.
34. A method of screening of candidate agents for treatment of a condition characterised by abnormal bone resorption, comprising the step of assessing the ability of
- 25 each agent to modulate expression or function of a polypeptide according to any one of claims 13 to 18.
35. An oligonucleotide primer selected from the group consisting of antisense primers having the sequence set out in SEQ.ID. NO:5, 6, 30, 35, 13, 16, 18, 27, 47, 50,
- 30 52, 54, or 55, and sense primers having the sequence set out in SEQ.ID. NO: 3, 31, 32, 14, 28, 34, 38, 39, 51, 53, 22, 23, 24, 25, 43 or 56.

1/37






Figure 1


3/37



4/37


*Figure 4*

5/37

*Figure 5*


Gene structure for mOCIL and mOCILrP1

Figure 6




mOCIL and related proteins

Figure 7




8/37



The deduced amino acid sequence of mOCIL with a predicted cytoplasmic domain, a transmembrane domain and extracellular domain containing a neck domain, c-lectin domain and tail


Figure 8a



The deduced amino acid sequence of mOCILrP1 with a predicted cytoplasmic domain, a transmembrane domain and extracellular domain containing a neck domain, c-lectin domain and tail

Figure 8b

10/37



The deduced amino acid sequence of mOCILP2 with a predicted cytoplasmic domain, a transmembrane domain and extracellular domain containing a neck domain, c-lectin domain and tail

Figure 8c

11/37

ClustalW Formatted Alignments





Figure 9




TRAP: tartrate-resistant acid phosphatase

MONO: mononucleate osteoclast precursors

*p < 0.025 vs control; **p < 0.005 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control

Figure 10A

13/37

*Figure 10B*

14/37





Figure 10C

OB + BM CO-CULTURE



TRAP: tartrate-resistant acid phosphatase

MNC: multinucleate osteoclasts

* $p < 0.025$ vs D₃ + PGE₂ treated; ** $p < 0.005$ vs D₃ + PGE₂ treated
439: (SEQ ID NO: 24); 474: (SEQ ID NO: 25)*Figure 10D*

16/37





Figure 11

17/37

*Figure 11 (cont'd)*

18/37




Figure 12A

19/37




Figure 12B

20/37




Figure 13

21/37





Figure 14A

22/37

*Figure 14B*

**Expression of OCIL mRNA during osteoclast formation
in mouse bone marrow culture**





Figure 15

*Figure 16*

25/37




Figure 17

hOCIL gene





Figure 18A

27/37



The deduced amino acid sequence of hOCIL clone 3 with a predicted cytoplasmic domain, a transmembrane domain and extracellular domain containing a neck domain, c-lectin domain and tail

Figure 18B

28/37




Figure 19B




Figure 19A

29/37




Figure 20A

30/37





Figure 20B

31/37

Mouse Spleen cell Culture + RANKL + M-CSF

msRANKL (50 ng/ml); hM-CSF (25 ng/ml); mOCIL protein (12.5 ng/ml).

* P < 0.05 vs control (RANKL and mCSF treated with buffer alone).

Figure 21

32/37

Figure 23





Figure 22



33/37

Figure 25





Figure 24



34/37





Figure 26A


35/37

T cell depleted spleen cell culture

In all cultures, cells were treated with sRANKL (50 ng/ml) and hM-CSF (25 ng/ml).

Figure 26B


36/37



In all cultures, cells were treated with sRANKL (50 ng/ml) and hM-CSF (25 ng/ml).
 Note 0.5 ng/ml MBP alone was not performed.

Figure 27A

37/37



In all cultures, cells were treated with sRANKL (50 ng/ml) and hM-CSF (25 ng/ml).
Note 0.5 ng/ml MBP alone was not performed.

Figure 27B

SEQUENCE LISTING

<110> ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH

<120> INHIBITOR OF OSTEOCLAST PRECURSOR FORMATION

<130> FPI3129

<140> PCT/AU00/

<141> 2000-07-19

<150> PQ1675

<151> 1999-07-19

<160> 56

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:cDNA

<400> 1

atgctgggca cgtacacaca a

21

<210> 2

<211> 321

<212> DNA

<213> Rattus rattus

<400> 2

cgctctagcc cggccacgcg tcgactagta cagctccaaa tctgtgcccc tcagttcttc 60
 cctcctgttta tctctagagg aagctgtgga gagattccag gatcatctga aacagagaca 120
 catgcattct cggctttttg tgttttatta cagaatttct taagcagata caaagggagt 180
 tttgattact ggatcggcct gcacagagag tcttcagagc acccttgga gtaggacagac 240
 aacactcagt ataactactc gtatgtttca caatgttttt tcttctactg tgttcatgtc 300
 ttgttgaggt cttgtgtgtga c 321

<210> 3

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 3

tgagtgttgt ctgtccactt ccaa

24

<210> 4

<211> 402

<212> DNA

<213> Rattus rattus

<400> 4

acagtaaaat gctccaagga aagcttccca gaaacatccc cctggagtat cctgctgggc 60
 cttactgctg ctacgtagtg atcattgtcc tcaagtgttag ctgtagttct ctttctgttg 120
 ctttctcagt aaaaaagaca gccaaagatct caaccataaa tacttatgct gcttgcccga 180
 gaaactggat tggagtggga aataaatggt tttattttaa tgaaatacca agtaactgga 240
 cattgagcca gacctctgt aaggacaag gggccgagct agcacgattt gacaccgagg 300
 aggagctgaa tttcctaagg agatacaaa ggagttcagg ttactgggcc ggtctgcaca 360
 gagagtcac agcgaccct tggaaagtga cagacaacac tc 402

<210> 5

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:cDNA

<400> 5

gaaacatccc cctggagtat cc

22

<210> 6

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:cDNA

<400> 6

ccaagtaact ggacattgag ccaga

25

<210> 7

<211> 1302

<212> DNA

<213> Rattus rattus

<400> 7

```

acagtaaaat gctccaagga aagcttccca gaaacatccc cctggagtat cctgctgggc 60
cttactgctg ctacgtagt atcattgtcc tcaagtgttag ctgtagttct cttctgtgtg 120
ctttgtcagt aaaaaagaca gccaaagatc caaccataaa tacttatgct gcttgcccga 180
gaaactggat tggagttgga aataaatgtt ttatttttaa tgaaatacca agtaactgga 240
cattgagcca gaccctctgt aaggaacaag gggccgagct agcacgattt gacaccgagg 300
aggagctgaa ttctctaagg agatacaaa ggaagttcagg ttactggttc ggtctgcaca 360
gagagtcctc agcgccacct tggaaagtga cagacaacac tgagtataac aactcggttt 420
ccatcggagg agatgaaaaa catggcttcc tgagtgcaca tgggttcacg agtggcaggg 480
gttatatagt gaggaagtcg atttgttaga agcccaacag ctacacctca cagtgcctgt 540
agttttgtgt ccttgggtga gactttgtcc taacagtcac gaggaacaca gaacatggta 600
tctacagtcg ctgaatcatg aacaatctgc taaaatcatc ttcaattcat aatgtgtgtg 660
gacatctaag ataacaactg aggcataatt tgcttgggag atcatgaatt gttctatatt 720
aaataggtat tcaggtatga gctggttctc acatcttaaa cataaactga atcatgtcag 780
tattagtatt ctctactttc tttttctctc catttaaatt atattatta ttatatctc 840
aaataccgtc cctccttctt tcccccttct agagttgttc actccatacc cctcatctt 900
tacttctgaa gagatgttcc cccacccccc tctgagtatt tcccttctct tggactttag 960
agctgtcacg gattaggtgc atcctctcat agtgaggcca actgtaggga gctgcgacat 1020
gccgtgcctc aaaaatggtgc tgggttccgc ctccaccct ccaacacagt agcgctcctt 1080
gtagtaaaca agtccttatt tgactatgcc tgctctggcct gctaggttca gcatagtgc 1140
agcctgtctg catgacccat gtggcacgtt ggggttggtt ggtgttggaat acataagctg 1200
atgtagggca ttccccctgg gtagtagatg attgtatcaa ggttctgaa taaactgctt 1260
gaagaaaaaa aaaaaaaaaa aagtactagt cgacgcgtgg cc 1302

```

<210> 8

<211> 738

<212> DNA

<213> Rattus rattus

<400> 8

```

agtaaaatgc tccaaggaaa gcttcccgaa aacatccccc tggagtatcc tgcctgggct 60
tactgctgct acgtagtgat cattgtcctc agtgttagct gtagttctct ttctgttgtt 120
ttgtcagtaa aaaaagacag caagatctca accataaata ctatgctgc ttgcccagaga 180
aactggattg gatttggaaa taaatgtttt tattttaatg aaataccaag taactggaca 240
ttgagccaga cctctgttaa ggaacaaggg gccgagctag cacgatttga caccgaggag 300
gagctgaatt tcctaaggag atacaaaggg agttcaggtt actggtccgg tctgcacaga 360
gagtcacacg cgcacccttg gaagtggaca gacaaacact agtataacta ctacacagag 420
ctcagatggg gagcggggac tctgaaatcc cagaaagcca ctgcagaact gcaagcctga 480
gattttgatg tccactattt gcattggctgc acctgttcag gaaagcacag attttaagga 540
cattcggaac ctcttttaa gttttgtcat cacagagcac ccaaaacagt cctcgaatca 600
caggcccgat cccatccacc gttaaagcac ctttgagcaa ttaataaaga agtgcgtgtt 660
cccattgtga aaatgaataa aaacagaatt ggaaaaaa aaaaaaaa aaaaaaaa 720
aaaaaaaa aaaaaaaa 738

```

<210> 9
 <211> 620
 <212> DNA
 <213> *Rattus rattus*

<400> 9
 agtaaatgc tccaaggaaa gcttcccaga aacatcccc tggagtatcc tgcgtggcct 60
 tactgtgtgc acgtagtgtat cattgtccctc agtgttagct gtagttctct tctgtgtgct 120
 ttgtcagtaa aaaagacagc caagatctca accataaata ctatgtctgc ttgcccgaga 180
 aactggattg gagttggaaa taaatgtttt tattttaatg aaataccaag taactggaca 240
 ttgagccaga cctctctgtaa ggaacaaggg gccgagctag cagcatttga caccgaggag 300
 gagctgaatt tcctaaggag atacaaaggg agttcagggt actggctcgg tctgcacaga 360
 gagtcatcag cgcacccttg gaagtggaca gacaacactc agtataacta ctgcctttcc 420
 atccggggag tggaaagata tgccctacctg aacgacatcg ggatcagcag tgcaggggct 480
 tatgcagaca aaagatggag ctgtagcaaa cttaacagct atagcctcca atgcaaaact 540
 cctttttctc ctatgtagct ttgatcaag agagatgctt tttagtctgc taaaaaaaaa 600
 aaaaaaaaaa aaaaaaaaaa 620

<210> 10
 <211> 1907
 <212> DNA
 <213> *Mus musculus*

<400> 10
 ccgaatgttt cctgcaacac aaagatgaca accccagcct gccaccattt gaaaggccag 60
 aggctgagge catgtgcacc ttccatttca tttctgtatg taagaaatat tctctatctg 120
 gtttgatagc actttgggag cataggggaa agagtagcac ccacagataa caggcctaaa 180
 agcgtctctt ggtaaatgct aggaaggaaa aaaggaggtt tggcagtgga ggcctatagct 240
 gttgagcttg ctacagatcc acatccgaag tgaatagatc ctggtagctc tgatcccggt 300
 gttgttcagg taggcaaatc ttctctctcc ccggatggga atcgtgttgt taaactcagt 360
 gttgtctgtc cacttccaag ggtgctcttt gccctctcag ctttcaagtt tcaatcctgt 420
 agtggaaact cagctcctca gctctgagat gtgtgtcaca aaggcttccc taacctatgt 480
 tagtcccaca ggcagcccg aggtagaagt gggtaaaatt ctccaaggaa aaaggcagcg 540
 aaccatctcc cctgagctct gtgctaagct ttactgtctc tatggagtga tcatggctct 600
 cactgtagct gtaattgtct ttctgtgtgc ttgtgcagca acaagacag aacagatccc 660
 agtcaacaag acctatgtct ctgcccgcga aaactggatt ggagttgaaa ataatgttt 720
 ttttttttct gaatacccaa gtaactggac attccgccag gcctctctga tgcgcacaga 780
 ggcccaacta gctcggtttg acaaccagga tgagctgaat ttctaatga gatacaaggc 840
 gaattttgat tcttgagatt gctgcacag agagtgttca gagcaccctt ggaagtggag 900
 agacaacact gagtataaca acacgattcc atccggggag aggaagattt tgcctacctg 960
 acaacaacag ggtacaggga attccgggac acccgtcagc attcctggag aaaattcggc 1020
 attcatgaga aaactgtctt tctactccag tgcctctcagt gaccaatggc tactgagtgc 1080
 tgcttctatc gaactgatct gaattgaggc aaatgtaggg ttggcttctc gcagggaagac 1140
 tgttcaaaag caagctcttt ccctctagtg tgcctgggct tagtgcaact tagtcttgtt 1200
 ggcagcgtgt ctcctcagtc tggctattgt gatctttccc atagaagag tcagggaacga 1260

```

ggggaaggga aagatagagg cctaagggtga aattttaaaa aactcaatct gttggtttga 1320
tttgtggttt catgtttggg tgcatttgtt cttgagacaa aagtagaac ttgaaatact 1380
ttatttaaa aaacagagtg cctggcatta ttaataaac ctaatgtaag tctatgaaga 1440
gtttcactta aatacattta tataaagagc caatgtttaa agtggttatgg ataataattc 1500
ttcaagggtg tgggtgtatt ggaacaagtg ttctttctgt cagctagatt cctggtataa 1560
aataatttga ctgcagggaa gttgacagaa agcattactt ctgtatgcta caaccttcta 1620
aaattgtgtc ctgctccac ccatgttggt gtttgaatga aaatgtggcc atagtctcat 1680
atttgatgt ttaatcacta gggaaatggc ctgtttgata ggatagaag gatggaggc 1740
gaggcctatt ggaggaaagt ccatactgt gatggccttt gcctagtctg tcaacccag 1800
agttttcatg cctgagtgct ccctgctgga taatggagta accctctgaa actgtaagca 1860
agctctgat taaatgcttt catttctaaa aaaaaaaaa aaaaaag 1907

```

<210> 11

<211> 9862

<212> DNA

<213> Mus musculus

<400> 11

```

tgcattacac acacacacac acacacacac acacaaggcc gggcagtggt ggtgcacacc 60
attaatccca gcaactggga ggcagagaca ggcagatttc tgagttcaag gccagcctgg 120
ctcacagagt gagttccagg atatccaggg ctacacagag aaacctgttt tcaaaaaagt 180
tactttttgt accttgaagt ctaaaatatg tctcaactct gtttgtttct ttacagtat 240
aacatgtctc ccccccccc ccgcccgcgc agtttttctg ttccagatct aggtaggcac 300
ccaactctct gcagcttctc aagtccagtg atgtaaaaat aatcccacaa ctcaaaaaat 360
atagagggaa gacagcgggg aaaaaggggc gggctcattg ctctagcaag aagatagtagg 420
tgcatagcct cccatgccag attgcttgga gacaggagaa aaactgtacg tatttaatga 480
aatgctaact aaactaaagt gggggaggct tcttcagggg agctggatct tgctcctgtt 540
agcctgccat agtgggtcta tatagaccag ctgaggtcgg ggtgggttgg atggtgggag 600
ctctgtctgt gtcggaagt accgatgcc ctctgngctt tctggtatgg ccaatgttac 660
ttaaatacgt ttggggaggag tgcaaccttt tgagtttgta aataaaagca ggtgccaga 720
ttcctggagg attgactgga ggaccttggg ggtgctctgg cacacctgc caccagccc 780
ataccttaag tgcacctctc acacacctac ctacaacttt cttttcaggc tcccacagta 840
ctcccccttt cccaaaacct caagcttttg gaatttctct ctcttcccaa ggacaggggt 900
atcaggtaat actctttctg gccttaaatg actcttctgg caccagggaa ggatcaggtt 960
ttttccagta ggggtggggg gggagattta tcccatctac aaatccatct acagttttag 1020
ttcactgggt gctgggaatg aaaccaagtc tctctctgca agagcagcaa gctcctctcc 1080
ctgttgagcc atgactttac ccccattta atacttttgt ttaggataaa aatatacaatt 1140
ttctgaaaa gcagagttca caattgttgt tagatcaatg gcctagtggc agcctgagga 1200
taccaggcaa gctccttcag agtggacagc ctagctgcta agatgatgg aaatactgtt 1260
ctgggaggtg ggggacaggt cgaggaaag ggagacctaa ctagcctctc ctcaacctct 1320
agggccctac tccatgccat cctgtgcaca cctaaagtac cctctctcac ggctatcctg 1380
tgcctctaaa cagaccctta atcagagtgt agaacagggt ctcttttagg cagagtatga 1440
ggatgatttg gctctgtgcc ttgtactgtg agctatagcc aggttccacc aagtcacata 1500
ctcctcacag taagccatag cgctgttgtt gttgggaaaa cttagaaaaa taagaatttc 1560
ctttgttctt cagacttttc tatgggttaa aaatggcagc caggtcctac agcagtggtc 1620
aagggcata aagcaactga atttggtaga agttactctg tctgctgtct cacagtgggt 1680
tctctagaag ccaccgcagc ttctctaagt ttttcacctc ctctgactca taccaaaaga 1740

```


gaaagggtcat gagtaataact actgtttctc agataagcca tgtgctctctg agggcaagta 1800
 gtctagatga acactagagg gcccttaagag agtccatgac tgagcaataa aatgggtgagg 1860
 tctcaaaaag gcgacctttt tcatcacctt ccggacctga gaacaaatct tggctactta 1920
 aaacaggcct gtgcagcctt tctcctctca ttggtgcccc tgccagtgag caaatccaaa 1980
 cagttcaagg ccagagcagg atgtgggttt tgattgacac agtaagatga acgatcatgt 2040
 tctttgtttc attatggtga atatattcaa aatcccttgg gctagcttta aaatcggta 2100
 cattgttgtg agcagatttc atcctactgt gcccttgaac aacagatctg atatcacttt 2160
 aaagaaattt ttacttgttc tgtctctact cccacagacc cctggtaaga gatattttta 2220
 ctgtcttgtg tgtttacaag agccagcaca tggaaacac tagtaggctt ctctgctgac 2280
 ttaataagcc aactcgagct gaattaaaag tagaaaagca tatttatttc agaacagttc 2340
 cagggtcaagg tcaccagctc cagggcacaa ggtggaagtc ctgccacagg tatggcaggg 2400
 aagggtgttt tatagattgt tggtagaagg aaatgacctg tctgccacaa gctgggctgt 2460
 agtcccagcg tggcaccta ggctggggac aaggttgcta cagctaccat gaattgtgaa 2520
 ctgggcttgt ggtgccaggg ctgggggtgtt gggagggtgt ggggtatggg caagtccagg 2580
 ctgccaaaca aacagacatc agcatctatc agtggatgag tgtggaaaaa ctgtgataca 2640
 tactcccata tatactggaa tactatgtac tagtaagata ggaatgtcttt tgtgacaaca 2700
 tggctggacc tgggtgacat gctgagacaa attagtcagg cactgaaagg ccaacattgt 2760
 tcatcagttg tagaggggtt tgttagctaa aagcagacag gagtttacac tcttttcttc 2820
 gatctggaaa gatttttgaa atcacagtgc agaacctgaa atcacaatga aaccaaacca 2880
 ctcccttaca atctgaagg gtttagaaat ctcccaagac ttcctttcta tagggagtgt 2940
 gaggagggtt gaggagggtt ccagcagca catggctgag aggtgctggg gctggaaatg 3000
 agcacaggcg aattttattt gctatcattt tataattctg agaactagaa agaattaaag 3060
 ctgggagttc tgtgtgtagt caaatgcaa aagctcagtg cttaaaggct tcttcttaat 3120
 cctaaggctc ctttccctcc ttgttaattgt aatagaagct ttctggtatt ttaggtgtgc 3180
 gaaaatgcac aaaaatgcaag gattaaagtc agtgaaaaact agtgaaaaa taaattagc 3240
 actcaataaa attaatctat ttggtatata tttctgtgaa ttttgaaaaa atataatcag 3300
 tgtttcttca ttaagatata taggggtctg agacttggtt caaccactga gacatcttat 3360
 tgctcttgct gaggactgag gtttcactcc cagcacacat atgggtggtc aaaccccacc 3420
 cctaattcca attccaggga tccaatatat tttctaaatt cctctaacag taatcatgca 3480
 tgtagtacac tacatacata cacatacata ttacattcac acattcttac atttagctga 3540
 caaagcactc ttaaatgtaa aataaataag actaaaaacag tcattttaaa aatatataca 3600
 gacccctcac cctacctgtt tcccgttgtt ctgctgcaga cactctcacc actcctccgc 3660
 cacagccatg agtagtcacc ttccagatg acttaaaatg ggtccatgaa gcagagaagt 3720
 ccacaagag ttctttcagc ttgtcacagc aatgccttct gctcatcact cacatgccag 3780
 tgccaatgag tagtgtgtca gaaacatgca ctgctggtga gatgctgagg catataacc 3840
 atagcatcgc ctacacagaa tcatgctctg agttcagaaa tttttaagaa tctcaccagc 3900
 aaatactatg caaagagggt gtgaaaagct gtcaggaaac ttctagagaa gtgataggag 3960
 gaagtgaata gtggcagttg ggggtctctt cacaaaggaa actgggaact cctgtagctc 4020
 tctgaccttt gcattgagctt actttcgggt tagtttaggg acactttggg gaagaagccc 4080
 ttgggacatt tggcctgtta aagtggtcatg agataaggca agcacaggca tgtgttccaa 4140
 gtgtgttctt tggttgagag gtttaccttg ggggatattt taatggtcac 4200
 aaatgtgtca ttttcacagg gatccttaaa gctgctgcaa atattcacat aaagatgtct 4260
 ttgaacctga attcctttcc agcatgggaa tatgtgggta ggaatgggagc atatcagctc 4320
 ttcaccttac aaacagcttt gtgaagctg taaaatttag ccttaagaag ttgttagttc 4380
 tacctcaaca tggacatcca catcaatgta taacctctct gttatgcaga cagtgtattt 4440
 gctcttaaat cgaagatgat ttgcccacag acaagttcac aaacattccc ttaactttctc 4500
 aaaaactaaa tgactcttatg atattaagtt ttgctctggg gatctcttag ctcacaaagt 4560
 gactgtagaa atttatgcct atttatttat ttattttatt ttttaggaga cagatggaag 4620

ggtgtttcag tagcacacac ggggagtgat gccatctttt cectgtctaa agactgggtc 4680
 atctctgggt aagtggtctc ttgaccaccc acatgtgttt gacctcattg tggagtcctg 4740
 ttttctgctg tgtttgttca gtgtctactc tgaatgctag accaggtctt cattcctggt 4800
 cccatgagaa catgagacat caggtcaggc cttgtgatct ttctgatttt gacctcttca 4860
 ttctcagaat aatttttgac tattaatttt tgactctttt taattttcat attactttctc 4920
 atacaacttg gtgctatgat tttttttttt ctgaaggcaa ctacatctct ggaatagtgt 4980
 acacatatat gtgtgttcag aaattgttga catgagcaat atggagtggt ctagttcatt 5040
 atgtgtttag cgtctccttg atttctttct ttatttcaaa aatgtaacat tgacagtggtc 5100
 tctgcttga tagatatcta tggatttggt gcattctctag tgcccaccaa ggttaggaaa 5160
 gttctcagac ttctgaata tggatttaca gaggtctgtg agctcttata ttgggtctag 5220
 atttaaccca ggtctctga aagatcaaca aatgttcgaa accactgagc caactttctc 5280
 tttattttct ttatatattt acatgtagtt ttgtttatgc tgactatgaa catctatttt 5340
 ttatatttgt aattttatgt ttttttggca ttactgtcta agatattaat ttccacttga 5400
 caggacaata caactgattt taccatgctg tcacctgtgc ctgcagtttt ataaactcat 5460
 tttttttttt tttttttacat ccaacggctt ttgttagatt tgtttggatt ttattgtaga 5520
 tagaacctgt tcatctgtga aaagaaacac ttccactgtt ttctgagaag cataaacctc 5580
 cttctgtctt ttaagagact cattttatgt atgtggctgt ttgcttgcag gtttgtacat 5640
 aacatgaatg cccagtgtgt acagaagcca gaagaggcca atggaccctt tggaactgga 5700
 ggtgtcgaat gttgttaagt accttcaatt caagtctctt ggaagagctg aaagagatct 5760
 taacagctga gccattctcc agacacctga cctattttct ttgtctctgc gacgacctcc 5820
 tgggaaagt ctacctggag taatgagcag acatctgact ctgtctctg attgtctggga 5880
 acacattcat aatggcacca ttgagagtcg agctgactga agttggaact acgtctttgt 5940
 ttttaatgga tgaattttgt aggtttgaag aagtctcttt cacttccatt ttccacatat 6000
 tttttgtgtt tattgagata ttcttaattt ttctcttttt cttattttgt aatacatcta 6060
 attacatcaa ttatttttct agtgttttcta caactcttcc tagccaaggc gctttttatg 6120
 gagccaaaac cagatttttt ttgtttgcat gtcactggga tctccactcc gtccattttt 6180
 gctcttccat tattcacctc gatttcaagt atcagaagtc tccctggcag aagtctctgt 6240
 tccatctctc ctgaactctt ttctacctat gacatctttt gtggaccagg cctctctcta 6300
 aaagggttgg cagaagcctt tcaggaaact ataggcaatt gtcaagtggg ttttgtgtgt 6360
 attttatttt attttattta agaaattctt gaaattcgca ttcttatatt catattttac 6420
 agataaaaatt ctccaaagaa aaagtctcag agccatctcc cctgagtctt ctgctaagct 6480
 ttactgtctg tatggagtga tcatggtctc cactgtagct gtatgtgtct tttctgttgc 6540
 ttgtcaggtt aagtgcata cctccaaat tctgtgacac tctgtccata ttccacttgc 6600
 cagttatgct ttctaagcac tgtgatccag gcactgtggt aagggtctta gaggaacac 6660
 actggaaggt cctgttctct gagaatttag gttccaaac gaagatgcag tgaaggaaac 6720
 cagaggcttt gatggggaca tcccgggaa gatgacatcc agcaagctct agacagagat 6780
 tcaggggaca taggtccctt tgggggaaca attcaaggca gagaataaca agagggaatc 6840
 tcccttlaag taatttgaag gtgagggcag gaaggttaca tgcctttgac catgacctat 6900
 gagttagtat accaggtcca actctatttt gaaagtatta aatggaaggt tcttgaagta 6960
 agaaaattat aggtattttg taccacaata ttcaagaatg tgcaatacaa tcttgcactg 7020
 tctcttlaag tatttgaagt catcctttag tgcacgcta tatcacactc 7080
 acccaaaaat tctcatagaa atctcaatta tcaggctggg tgtcagtagg tgcctctaca 7140
 gatgtctgc tgctgtagca atccccactg tagtcaatgg tcatccaaag ctgagaaagt 7200
 gactctgcta tagaagtcca ctccctggga gccctatgag cctgagagca ctgagagaga 7260
 atgggacaca gggccacggt gggaggcctt tagttaaagg cacatctcga tcaggagagg 7320
 attctacag atcagttagg aaagtacca tcagatcac acctcacgc tgagctcagg 7380
 agagtgtggc aaaaacagag aagactgctt tgctatgac catcatattt tctacatttt 7440
 agtaacaaag acagaaacga tctaatcaa caagacctat gctgcttgcc cgaaaaactg 7500

```

gattggagtt ggaataaat gtttttattt ttctgaatac acaagtaact ggacatttgc 7560
ccagaccttc tgcattggcac aagaggccca actagctcgg ttgacaacg agaaggagct 7620
ggtaagcaat gggcagggat tggtttgtct gtctgttctg ttgaatatta tattgccttg 7680
cagaagaact tctctcatga agtgctcata gtcagctgga aggtcaataa tgcattttaa 7860
agattagagag ttacagatga gggccgagga agggatccca cccaagcaca tggagacata 7740
gggaattgta gtgtgtgcca ttgtctgatg cttgacttct gactggagcc ctgagatagt 7800
caagaacat tctctcatga agtgctcata gtcagctgga aggtcaataa tgcattttaa 7860
ctgggatacc tgggtgacccat gagtggtttc coatatgctg gcataatgtg ggtacagaag 7920
gagacaactg ataataactg cagtggaaag ttaaccacga actgtccaaa ccacagagga 7980
atgtgacctc cagttacatc ctctgtttat ctctagagaa aggtgtggag tggagagact 8040
ccaggatcat ctgaataaaa tagacacatg tattcttgac ttttttgtgt tttatgacag 8100
aatttcttaa ttgatacaaa ggcaattttt gattcttggg ttggactgca cagagagctg 8160
tcagagcacc ctgggaagtg gacagacaac actgagtata acaacatgta tgttttcacg 8220
atgttttttc ttctattatg ttcatgtgtt gtgatatgtg tgtgtcgtgg ctatgagaga 8280
tgaagtcaa tctcatgtga agccaactgt actgggaaga aagaaaaaaa aatgaacctt 8340
tgcttggagg tgtggctcag ggttagagag tgtgtataaa tgcaatatcc aatccccaga 8400
aagctctaca cccccacaaa tttaaatact tcagagggtt tctgtttat tgacctgcat 8460
tttcaaaacc ttgtcatcat gtcattttac tcaaaatatt taccataatg atggtgtctg 8520
agagttageta ttgtttgtct tggctccaac taaacattt ctgtgtttga taatgtctct 8580
gtgagggata tagacagagc cttagatggg cagtgggggc tctggaatcc cagaaagcca 8640
ctgcagtatc tgcaagcctg agattcagct ttccactatt tgcatgtctg cactgtttca 8700
ggaaagcaga gactctaagt acatttggaa cctcctctaa agtctcgtca tcactgagca 8760
cccaaaacag tcttgggttt gagctgtttt actgggatgg taaatcacag actcagtcac 8820
atccatcact gaagccctta gagcaattta ctaagtgggc gtccccatat ataaaaatgcc 8880
taaaaacaga ttgaaatca ccttgggtgg ggtcactcat ggctgcagtt catttgaaca 8940
tggcagcgag caccagccca atgccttcta cacacattac aggtaccac atggacaaat 9000
gacaaaggag tgggtgtcaa atcctgagaa tatgagacag taggtgtaaa actaatgcag 9060
gtgattcctc agggactttt ttgattcatat taccaaaaat tagtggagac tgggtgagatt 9120
tcatttgcag agcaaatgca gttctgggct ctgtaggctt acttttttgg ttctttttca 9180
ggatttccat ccaggagggt gaaacatgtg cctacctgag cggcaatggg atcagcagtt 9240
ccaggcacta tatacctcgg atatggatct gttagcaagct taacaactat agcctccact 9300
gccccactcc tgttctctgc tagcatttac caagagactc ttctagcct gttatctatg 9360
gggtgctactt ttccctcat ggtcccacag tgctatcaaa cgggatttag aatatttttt 9420
aacgtcgcaa atgaaaacca tcaaggctgg agagattgct ccgtagttaa gagactgact 9480
gctcttctgc atgtcccgag ttcatatctg agcaaccaca tgggtgctta caaacatctg 9540
taatgacatc ttatgtctct ttctgtgggt tgtgaaaaa gctacactat acctacatat 9600
gataaataag taaatcttaa aaaaagaaaa gaaaaccacc tttagagagt gcacacatgg 9660
aggattacaa gaccatagat gagtttttaa tagatgtcag cactcatacc ttaagcctaa 9720
agtacaacta atgttaggga accccaattt tatgatatta aggtttttgg cagagaattc 9780
ttcttttgaa ttatagagc cacaataatg agtcccccaa catgggtgta accttaata 9840
atgaaagcag aatggctggg at 9862

```

<210> 12

<211> 990

<212> DNA

<213> Mus musculus

<400> 12

```

gatagtggtg cagagcctcc catgccagat tgcttgga caggagaaaa actgtttgta 60
cataacatga atgccagtg tgtacagaag ccagaagagg gcaatggacc ccttggaact 120
ggagataaaa ttctccaaag aaaaagtctc agagccatct ccctgagtc ttctgctaag 180
ctttactgct gctatggagt gatcatggtc ctactgtag ctgtagtgtc tctttctgtt 240
gctttgtcag taacaaagac agaacagatc ctaatcaaca agacctatgc tgcttgcccc 300
aaaaactgga ttggagttgg aaataaatgt ttttattttt ctgaatacac aagtaactgg 360
acatttgccc agacctttctg catggccaca gagggcccaac tagctcggtt tgacaacgag 420
aaggagctga atttctaata gagatacaag gcaaattttg attcctggat tggactgcac 480
agagagtcgt cagagcacc ttggaagtgg acagacaaca ctgagtataa caacatgatt 540
cccatccagg gagtggaaac atgtgcctac ctgagcggca atgggatcag cagttccagg 600
cactatatac ctccgatatg gatctgtagc aagcttaaca actatagcct ccactgcccc 660
actctgttcc ctgtctagca ttaccaaga gactcttctc agcctgttat ctatgggtgc 720
tactttttcc cctatggtcc cacagtgcta tcaaacggga ttgagaatat tttttaacct 780
cgcaaatgaa aaccatcaag gctggagaga ttgctcgtga gttaagagac tgactgctct 840
tctgcatgtc ccgagttcac atctgagcaa ccacatggtg tcttacaacac atctgtaagt 900
acatcttatg tcctcttctg tgggtgtgtga aaacagctac actataccta catatgataa 960
ataagtaaat cttaaaaaaa aaaaaaaaaa 990

```

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 13

tcccatgccca gattgcttg

19

<210> 14

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense DNA

<400> 14

gggaccatag gggaaagagt ag

22

<210> 15

<211> 721

<212> DNA

<213> Mus musculus

<400> 15
 tcccatgcc a gattgcttgg agacaggaga aaaactgttt gtacataaca tgaatgccca 60
 gtgtgtacag aagccagaag agggcaatgg accccttgga actggaggta aaattgtcca 120
 agggaaaatgt ttcagaatca tctccactgt gtctcctgtt aaactttact gctgctatgg 180
 agtgcacatg gtccctactg tagctgtaat tgctctttct gttgctttgt caacaaaaaa 240
 gacagaacag atcataatca acaagacctg tgctgcttgc tcaaaaaact ggactggagt 300
 tggaaataaa tgttttttatt ttcttgata ccacgtaac tggacatttg cccaggcctt 360
 ctgcattgga caagagcccc aactagctcg gtttgacaac gaggaggagc tgattttcct 420
 aaagagattc aagggggatt ttgattgctg gattggcctg cacagagagt cgtcagagca 480
 cccttggagg tggacaaaca acactgagta taacaacatg aatcccatcc taggagtgagg 540
 aagatatgcc tacctgagca gcgataggat cagcagttcg aggagctata taaatcggtat 600
 gtggatctgt agcaagctca acaactataa ccttcattgc caaactcttc ctgtctagca 660
 cttaccaaga gactcttctt agcctgttat ctatgggtgc tacttttttc cctatgggtcc 720
 c 721

<210> 16
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:DNA

<400> 16
 tggaaactca gctcctcagc tctg 24

<210> 17
 <211> 713
 <212> DNA
 <213> Mus musculus

<400> 17
 tggaaactca gctcctcagc tctgagatgt gtgtcacaaa ggcttcctca cctatgctta 60
 gtcccaacag cagcccgag gaggtagaag tgggtaaaat tctccaagga aaaaggcacg 120
 gaaccatctc cctgagtgct tgtgctaagc ttactgtgta ctatggagtg atcatggtcc 180
 tcactgtagc tgaattgct cttctgttg ctttgcagc aacaaagaca gaacagatcc 240
 cagtcaacaa gacctatgct gcttgcccg caaaactggat tggagtggaa aataaatgtt 300
 tttatttttc tgaataccca agtaactgga cattcgccca ggccttctgc atggcacaag 360
 aggcccaact agctcggttt gacaaccagg atgagctgaa ttctctaagt agatacaagg 420
 cgaattttga ttctggtatt ggctgcaca gagagtgctc agagcacctc tgggaagtga 480
 cagacacac tgagtataac aacacgattc ccatccgggg agaggaagaa ttgctcacc 540
 tgaacaccaa cgggatcagc agtaccagga tctattcact tcggatgtgg atctgtagca 600
 agctcaacag ctatagcctc cactgccaaa ctcttttttt tctctcctag catttaccaa 660
 gagacgcttt ttgacctgtt atctgtgggt gctacttttt cccctatggt ccc 713

<210> 18
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:DNA

<400> 18
 ttgttcagca acaaagacag aacag

25

<210> 19
 <211> 1229
 <212> DNA
 <213> Homo sapiens

<400> 19
 cgggtgggag cgagagagcc tagaagccca tgtagccgag aatcccgcag cccagtagca 60
 cctccctccg tgcctccccg ccttttctgc agagctccgc cctggagtga aggaggagcc 120
 gtcacctgga gctccgaaaa aagcagaaga aggcgctttt tatttagcca gtgtgacccc 180
 gccaggggcct tctcggttgg gtgagcactc tctctgacca ggccatgaaa agaaaaatct 240
 gtgcgatgcc tccccacatg tcacgggact ctgacttgcc tttgtcgtca gagtttgcag 300
 aactttgggg gacctgagag gggagtgccc cctggacggg ccacggcgtg ctgtggccta 360
 agggcttttg gaaggcgga gagaggga aa cggcgctcta gtggcctgct tcaggggcac 420
 ccacggggcc tcccccaacc tctctctgat ccaacttggt ttccagcct agttggaac 480
 ttgtggatgc tgtacatca agaagacttg gcattttatt tgggaagatg acatctattt 540
 gcaactggtc ctgagcccct atttctctcc cacctttctt ggggaaactt gtttttaagg 600
 ggtgccactg tttttgtaac atgttgctcc tagctcttag cattcatggt actgttgtaa 660
 atggagaaag agtaattcac gcagagcccg ctttgcatat aaaactctgc aaagacaatg 720
 tctagcactt atatctccag taactcctgt caaggtttat tgttgcttgt tcatccattg 780
 cagtcctgac tacaagtgtg attgcacttt ctattgtttt gtcagaattt cctgaaaaga 840
 tacaaaggcc cttctgacca ttggattggc cttagaagag aatcatccca tcgcatttgg 900
 aaatggacag acaacatgga atataataac atgcttgcta tcagagggaag tggagaatgt 960
 gccttctgta atgacaatgg agtcaacagt ggcagaatct acatgaacag aaaatggatt 1020
 tgtagcaagc caaacaatta tgtctacagt tgccagttat gtcccactgc ggaatactacc 1080
 tagtagagct gtgagaagag ggccaccatc ctccagactc cagaatgggt gaatactacg 1140
 cagcttccac catgcccctg gaaaaactgc aagtaacaga cctgcacatg tatccctac 1200
 atctaaaaaa aaaaaaaaaa aaaaaaaaaa 1229

<210> 20
 <211> 1305
 <212> DNA
 <213> Homo sapiens

<400> 20
 cgggacaatg ttatgtggct cagaggccct ccatgtatc ttaactatc actctcctat 60

```

cctccaaga ataacactaa ttgacacct acaataatca cttatcact ccagttttgc 120
cttttttctt ccaaaacaat gccttttaag tctattttaa tgcagatatt tccctttaat 180
atcattttaa aatattttct tacattttta gacaggaatc agaataattt gctatgttga 240
atthccagtt acttggtatt tgttgatttc attcctgtgg tttagttgac atgaatctct 300
ccaattgaaa gggttaactt atatatgttg ctggaaagt aaatacaatt cttttaactt 360
tggaatatga ttaaatcttg gagatagaat aggttaagtt cataagatga caggtoattt 420
gcattctctt agtggaaaag cgaaggaatt aaataaaaaa aacactttga tgcctaatgt 480
tcttcgcagt attatgtctg tatttaattg ttaaaatggt ttccaataat tttttccagg 540
ttgtctgcatt tcaaaagagc attctattaa agctacctta atttggcgct tatttttctt 600
aatcatgttt ctgacaatca tagtgtgttg aatggttgct gctttaagtg caataagagc 660
taactgccat caagagccat cagtatgtct tcaagctgca tgcccagaaa gctggatttg 720
ttttcaaaaga aagtgtttct atttttctga tgacaccaag aactggacat caagtacagag 780
gtttgtgac tcacaagatg ctgactctgc tcaggttgaa agcttccagg aactgaattt 840
cctgttgaga tataaaggcc catctgatca ctggattggg ctgagcagag aacaaggcca 900
accatggaaa tggataaatg gtactgaatg gacaagacag ttccctatcc tgggagcagg 960
agagtgtgcc tatttgaatg acaaaggtgc cagtgtgtcc aggcactaca caaagaggaa 1020
gtggtattgt tccaaatcag atatacatgt ctagtgttta cagcaaaagg ccaactaatc 1080
tttagaagca tattggaact gataactcca ttttaaaatg agcaaaagat ttatttctta 1140
taccacaggt tatatgaaaa tatgtctcaat atcactaata actgggaaaa taccaaatca 1200
aatcatagta aaatattacc tgttttcatg gtgctaatat tacctgttct cccactgcta 1260
atgacatacc cgagactgag taatttataa ataaagagat ttaatt 1305

```

<210> 21

<211> 10221

<212> DNA

<213> Homo sapiens

<400> 21

```

gaattctctt tttttctatt gtttggaaata atttcagaag gaatgggtacc agctctcttt 60
cgtacctctg gtagaattcg gcagtgcaatt tgtctggaca tgggcttggt ttggttgggt 120
aggctaltta ttactgcctc agtttcagaa cctgttattg gtctattcag gaatctgatt 180
tcttctcgtt ttagtcttgg gagggtgtat gtgtccagga atttatccat ttcttctctg 240
cctgggtatc accagcaaaag gctgaagaaa agcaaaagatt gctgctgct ccttctcttg 300
gaagcttcat cccagagggg cagcaccagc atgccagctg agctgtctct gatgaggtgc 360
ctatcaaccc ctgctaggag ttgtctccca gtcaggagggc atgggggtca gggaccact 420
tgaaaaaggca gtctttccct cagaagagct cgagcactgt gctgggagat ccaactgetct 480
tttcagagct ggctgagcag aatgtttaag tctcctgaag ccgtgaccac agccaccctt 540
tccccaggt gtctgtctcc agggagataa gagttttatc tataagcccc tgactggggc 600
tgctgccttt ctttcagaga tgccctgccc agagaggagg aatctagaga ggcagtcagg 660
ctgcagtggc ttgtctgcac tggctttgct gcactgtggt gggctccgac cagtcaggac 720
ttcccccagg gctttgttta cactgtgagg ggaataatc actactcaag ctcagtaagt 780
gcggatgcac ctccctcac caagcttgag catctggggc ccacttcaga ctgctgtgct 840
ggcagcaaga atttccagcc agtgggtctt agcttgcgtg gctctgtggg gattggacce 900
actgagcaag accacttggc tccctggcct cagcccccct tccagcagag tgaatgatc 960
tgtctcaggt ggttcacagg tccactgggg tatgaaaaaa actcctgcag ttacttgtgt 1020
gactgcccaa atcggcacc cagtttgtgc ttgaaaccca gggttctggt agtgttggca 1080
ctccagagaa tctcctggct tgtgggttgc aaaaaccgtg ggaagagcgt agtatctggg 1140

```

ccagatagca cctcacagca cagtcctcca caactccctc tggctagggg agggagttct 1200
 ccccccctt gtgcttcttg ggtgaagcag cgcctccccc tgcttctgtg tgcctctgtg 1260
 gggtcgacc cacttgtgta accagtccca gtgagatgat cctggtagct cagttggaaa 1320
 tgcagaatc acctgccttc tgcattggtc tcactgggaa ctgcagacca gagctgtttc 1380
 taatcagcca tcttgccttc tctggtcttg tctgtttctt taatttggtt gatcacggag 1440
 cagtgatagc acaacaaata tgcacagatt tggggaaagt catcctgcac tatggtcttg 1500
 ttcaagaaat tacattttta tagttataat ttggtatcac ctgtttgtgt ataccaaaac 1560
 agatacaata cagctttgct tcatgttatg atttgttatt cagattacac cagttattat 1620
 tcaataacta gactgtattc tcatctcaca agagccaaat ccaaggataa tgggtgccatt 1680
 tgatagtaat gattctatga ataccagca ttctggtcta tcatagacac ttccagaacc 1740
 attgagttga aggtagaagg tggttatata atagaagatg aactggtagc tactgagggc 1800
 tcagtgacaa ctatctggag agacattcat tcatctcgat cccacatgaa gagagcattt 1860
 ctctgtalla tataagaagt gggtcagaaa agcctgtcca gtgaagtatt gctgccttca 1920
 aagtgtagaa aacctcacta aatctcctta gtggaaggaa gtctactgta caacacatta 1980
 ttcatattt atgatagtat ttacacatat acaaggcttt ttacatcaca gaaccttatt 2040
 tcacataagg catctctatc ctgcccctca ttttaccag tcatctggag cagcaatcgc 2100
 caaccttgtt ggcatgaggg accagttttg tgaagacaaa cgttttcatg gactggggtc 2160
 aaggaatggt ttggggataa tttaaagtga ttacttttat tgtgcccttt atttccatta 2220
 ttatcacatt tggtaaatat atataataa ataattatc aactcaccat aatgtagaat 2280
 cagtggaac cctgagctag tttttctgaa agtagatggt accatctgtg agttagggga 2340
 gacagtgaca gttcatcagg tattagattc tcaacaaggag cccacaacct agattcctca 2400
 cactgaagaat tcccaatagg gtttgccttc ctatgagac tcaatgccac tctgactctg 2460
 acaggaggtg gagctcatga ggtaattgta gtgatgggga gtggctgtaa atacagatga 2520
 agcttcaact actcattcgc tgcctacctc ctgctgtgca gctctgtccc tgactcatcc 2580
 atggaccagt actgacctat ggctagggg ttggggacc ctaactatga gcactggag 2640
 aactatctgt tctccaaagc tgatcaaatg ctatcattaa tgtatcta attttaagaa 2700
 agggtaacac tgttgagagc caaatagata catggcccag agcaagctta agttactaat 2760
 aactccttt ttcagctcac cctgctgaa ggcatgagtt tgaatctcag ttttgcatt 2820
 tgcctgtgaa tgtatgcaat tatatttagc atcatatttc tcaattgaaa aatgaaaaa 2880
 atacatttaa tacttaacag gagtgacaga aagtatatta gcacttggtt atttatacaa 2940
 tacaatataa aagtaagaaa tttttatttt atttattttt attttatttt cagcaataag 3000
 agctaactgc catcaagagc catcagtatg tcttcaagct gcagccccag aaagctggat 3060
 tggttttcaa agaaagtgtt tctatttttc tgatgacacc aagaactgga catcaagtca 3120
 gaggttttgt gactcacaa agctgatct tgcctcaggt gaaagcttcc aggaactggt 3180
 aagaaaaatg ttctggccag aatcaaaagt tcagccctac aaggatatgt ttctcgtgca 3240
 aattatctaa gaggtaggtt tagacatctg cttttacatt gatttttttt tttttttttt 3300
 ttttttgcat aacgaagag taacctagca tgtattatat ttacagtgta accactcaa 3360
 attaccttaa tattctggc aggaacaggg ccagagggca agcaagccag agccttcttt 3420
 gacttgtgag ccagaattgt gcaataaagg attagaaaag tattggtaga aaccaggtt 3480
 taagtttgta tgaagtttag aacattgttt caaaataaat caaacaggcc caagagcagt 3540
 ggcaatgcc tghtaatcca gcaatttggg agggcaaggc ggggtgatca cttgagtgca 3600
 ggagtttgag atcagcctgg ccaacatggt gaaaccccat ctcaactaaa aaatacaaaa 3660
 attagctggg catggtgcca tacgcctgta gtccagacta ctgaggaggc tgaggcagca 3720
 gaattgcttg aacctgggag gtggaggcct acagtttagct gaaatcatgc tactgtact 3780
 cagcctaaca gagtgagact ctatctcaaa aaaaaataa aataaaaaa ataagtcaag 3840
 caagaatgat gtcatagagg ttggtagact aaaaagctac agaaactctg tctccactg 3900
 agaaaactat tgaactgtca aaaactgtct gaagttaacta ttgtgaaat ctgcagctca 3960
 gttaaacact ggaagcatca aggggaagagt ttgataaaga ggatgataa ttttggttaa 4020

tgttgggtgaa ttccagcctt tccactcaat aataactatt ttccatacc c attattgca 4080
 gggatccatg ggaactgctg cccatgttct tgtaatgaat tccctgcagcc aggggtgaaca 4140
 ataagcacct ttttgtccaa atgtcagggt tattgctgat ttctgccttt gaatgctgag 4200
 gggcagacac agaagtggtc tatcattgca tcagctcctca tcagctgaag tggcttccca 4260
 aggatttaaa taaatagtagt gtgtttttcc tccctttagg aagcagtcac ttaagacaat 4320
 ttttattaga taactggctg acagcagaga taacagaaca gagatttcaa tgaccatgca 4380
 caacagagaa taaaaatagt tgggaaaaaa tcatgacca atgactctga gccacaaca 4440
 ccaagattgt acaatccctg aagagcaaaa taattaaagt accagagtta ccaacaata 4500
 gtattcataa tgtccagttc tcaaaaaaaa attcaaaaac attgcaaaag aagtatggtt 4560
 cattcacagg aagaaaaagt aatctgacag aaactatccc tgaagaggct cagatattaa 4620
 aaatatgagt caaaaatgtt aaatcagctg tcttaagtat aaccaatgag ttaaggagaa 4680
 ctgacaaaaa agctaaagga aaccgaaaaa ataataaatg aacaaaatta gaatacaat 4740
 ataaaggtag aaattgtaaa aaagaaccaa gcaaaaattc cagagctgaa aagtacaatg 4800
 actgaaattt aaaaaaattt ttaaaaactc aatgaagaag ttcaacagca gatttgagaa 4860
 gtaagaatgc agaaaacttg aaataaagt attgaaaca atccagata agaaaagaa 4920
 agaaaaagaa tgaagataaa taaattctaa ggaacctgta ggacatcagc aaacatacta 4980
 acatctgtac tgtagaaatc caggaaagag aagagaaaga gaagcagaga aatacactta 5040
 aagaataat gaacaaaact ttccaaaact tgaggaaata cataaatata tacatccaag 5100
 aggtcgaatg aactccaaaa ggttaaaact acattgagac aaatatagat 5160
 caagtgacaa aatccacag agagaatttt gaaagcagcc agaatgaagc aactcatcat 5220
 ttacataaga, ccttgaataa aattaatagc tgattttctc tgagaaacca tggagatcag 5280
 aagtgatgag aatggcatat ttaattgtct gaaagaaaaa ataaaactgc caacctgaa 5340
 ttctatgtat agcaaatgtt tcttcaaga atgaaggaaa aagtaacaca ttttcagata 5400
 accaataatt aagggatttt attaccagta gacatgtgct acagaaaatg ctaaggaaa 5460
 ccttttaggc tgaactgaaa gtacactaga cagcaattca gagctccaa aataaagaat 5520
 attcataaaa gtaacaatag aggtaaatat aaaaccaga attactacat gtgtcatata 5580
 gtttataact tctctattt atagctttct atatttatat ttatctataa ctctcatagc 5640
 aaatgaataa aaattataaa tatgatagt gtcatataat gtataaagat gcaatctgtg 5700
 acagtcttat gaagcaggga tgaagacata taggatcaaa atgtttgcat agttattgaa 5760
 gctatgttga tattatgaaa ttatattggt acaagtttaa gatgctaatt ataattctca 5820
 aggtaacacc taataaaatt accaaaatta tgcagaaaag gaaaaaagaa aaacaataca 5880
 ctataaaaaa ccaattaaat acaaaaaaag tcagttaacag acaacttgag aaacaagaag 5940
 atataagata tagagaaaac aaatgattaa atggcaaaag taaatcttgt tttagtaatc 6000
 accattaaaa gaaaaggatg aagccatcct attaaagggc tgagactgac aagttggcta 6060
 aaaactaaaa taattataaa agaaaaacaa gactcatcta catgctgtct atagagagact 6120
 tgccttagat ataaggacac aaagaagtgt aaagtaaaag gactgaaaaa gatattccat 6180
 acaaacagta gtaaccaaga tagtgccgag tggctatatt tttgtcaaac aaaaataaact 6240
 aagtgnaaat ttacagagaa aaagaagggt cattatgcat tgacaaaaat ttgacatag 6300
 ccaaatcaat atgtttataa atatatgtac ttaataatac agcctcaaaa tatatgaagc 6360
 ataatttgcct ataattttag ggagaaaaga acagtcttat gaaaagttag agaattgaaat 6420
 attccacttt caacctgaga ttaacaacct agacataaga tcaataagga aatagaaaaat 6480
 ttgaacaaca ctataacca attatcccta acaggcatat acagaagaat ctacccaaca 6540
 agagcagaaat attattctt ctcaaatgca catggaacat tcttaacca tatgttaggc 6600
 cacaaaacaa gtgttagtaa gtgtgaaat ttgaagtcat aaaaagatc ttttgcattt 6660
 acaatggaat gaagctagaa atcaataact agaaaaacca gaaaagtcac gcatatgtag 6720
 aaatttaaaa acccgctctt caacagccat tggttcaaga agaaatcaga agggacata 6780
 gaaaatccct tgagcaaaat gaagtataaa tacaataatg agctttatgg tatabactga 6840
 acatagttct aagagggaaa tttatagctg tgagcagtta actaaaaag aagaagaatc 6900

tcaaatccat agcctaactg tacactgtaa ggaactaaaa aaagtaaaac aaaaatagaa 6960
 gtcattctta tgatttgaaa gaggtaaaaga ttacctaatt aagtccttaa atttactaat 7020
 aataaagaaa attgtttata talttaattg cgttaaaatt cagaacttgt aatcataaaa 7080
 aggacagtac acattgacaa ggaacacag caaaggaaac cagcctatgc tgcctgctgt 7140
 gtgaggataa ttgggtacac ttacattagt ttgggtgtct ttctttctct ttcttttttt 7200
 ctctctttct ctctctttctg ttctgtctgt cgtctgtttc tttttgagac agaactctac 7260
 tctattgccc agcgtggagt gcagtggcgt gatcttggtc cactacaact ttgtctctcc 7320
 aggttcaaat gattctcatg cctcagcctc ccaaatagct gggattacag gtgcattgca 7380
 tcacgccag catctttttg tatttttttt aatagagag ggccttcac atgttggtcca 7440
 agcctagtct caaactcttg gccctcaggtg atccgcctgc ctgggctcc caaagtactg 7500
 gggattacag gtcttggtgt ggtgtgttca ttctttaaag ttgacaaaa gcatactctg 7560
 ggccctaaaa attctattct aggacaggtg ccaagaatgt catagtacga tacattccaa 7620
 acttgataaa accctggtgt caaccgatag tataatagat aaattggaga agagtcatac 7680
 aaaggagtag aatacagaaa caaaagtaac caaattatca acaatttctc tcatgtttaa 7740
 attatctctt ttgatctagt atgataatat agcacaccta ttctgtatgt attactaaaac 7800
 aatacaaaa caaaaggaag aaaattatga gtagttaaga atatagcata gcagcaacat 7860
 ttctgggaga ggatgggtta tgttagatta atgaatatca tctctgtgtt ttctgaaaga 7920
 attctctgtt gagatataaa ggcccatctg atcactggat tgggctgagc agagaacaag 7980
 gcccaactag gaattggata aatggtactg aatggacaag acagtaagtt ctaaaaactc 8040
 ggacagtaata ttgttatttg aatttacttt gcattaaatc tgaagtgttc tctagtatac 8100
 ttgtttaaaa aattctcatt ttaagggttag tcatgaaaga agatggtgac aacttgtatg 8160
 ttgcctcaagt ttccaaagtt cctcgaatga atcccaagcc tgcctggtg aggtagactg 8220
 actgtgaact tggctccagg cttatctatg tcattttcaa acactttcat ttaagcaaaa 8280
 ccatacaata tctttaagtc tgttctctac ctccacaaca aaattaaatt gcaactgttc 8340
 tctgattct acaggtgtga tgtgaggaac agaggttttg atgtatcagg gaaagattat 8400
 gagtgcagac aattatacct attattttaa ataagacaat agtttataaa ttttaaatg 8460
 ggtaagattt ggcaactagaa aattttaact caattgtata tttataggat cttcagatta 8520
 ctaaaaagat ttgagataat gctggaataa ttggattcac acaatttcac tcaattgttg 8580
 tctgagagat gagacagttt tgaagagcta ctttattgta atacattcat caatattgga 8640
 aataaactt tatttaataa aaagagcccc agactggaca ttggcaggtt tgaatagat 8700
 tttttctcat tagcttttga ccttggaagg gatggttaagt tttagaatc agaaaaatg 8760
 tacatttata cattgttgta tctacactgc cttgcacatt gtgactgctt cataaatatc 8820
 tagaattaac ttttattctt tattttacaa tacggaagta gtaattttc tctacctaat 8880
 tcttaaatg gttttttgtt tgtttgtatt tttagagagc agggcttacc tctgttacc 8940
 aggcgtggat gcagtagtac catcgtggtc cactgcagcc ttgactccc tggctcaagt 9000
 gagcctccca tctcagctc ctgagtagct gggactacag gtgtgtgcca cctgtcttg 9060
 ctcttttttt tttttttttt tttttttcag cgatgggttc tcaattgtt gccctgggtg 9120
 attttgact cctgactca agcaatctc ccacctcagc ctcccaaat gttggaatta 9180
 caggtgtgag ccacatgcc tggcctctca aaatatttta aggatcaaat atattattaa 9240
 ctaccagtt ttgggaaact gctcatcact taagaaagat taaaattata tatgattaa 9300
 gtaacaag ttccaacaat tagcaaatat tatcatagat gatagtatt ccaatgagca 9360
 aagaggaaaa atttataaat caaatgctga cctaaaaat ctgtgccaag ccattctaac 9420
 tcaagctaaa agcactgcag ttctcagtact aaaccacca ggaagtagg aggaataaaa 9480
 tcaagcaggt tttttagaaa tagctgctga gtctctcagtt atttaaggaa ccaaaattt 9540
 gggaaactgt gtaagaaaaa cgtgtcagac ttctcccatc agccagctaa ggctttggat 9600
 gtacttgaaa gaattattatg cttacagaca tgaattaggt ttgattcagg actttgcagt 9660
 attctctatg ttgatttata acatctctg ctaagcaag cctcagact aattagctac 9720
 cactacacaa ggaaaaacag cattattttt agaggctgaa ttaattgttag tttttctatt 9780

```

ttctcatctt cattctctct gctgttgaag aaatgttcag tggccaactg attctgcttc 9840
ttctcttgca ggtttctctat cctgggagca ggagagtggtg cctatttgaa tgacaaaggt 9900
gccagtagtg ccaggcacta cacagagagg aagtggattt gttccaaatc agatatacat 9960
gtctagatgt tacagcaaag ccccaactaa tctttagaag catattggaa ctgataaact 10020
cattttaaaa tgagcaaaga atttatttct tataccaaca ggtatatgaa aatatgctca 10080
atatcactaa taactgggaa aatacaaatc aaaatcatag taaaatatta cctgttttca 10140
tggtgtctaat attacctgtt ctccactgc taatgacata ccgagactg agtaatttat 10200
aaataaaga gatttaattg a                                     10221

```

<210> 22

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 22

gagtgtgtgc tgtccacttc c

21

<210> 23

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 23

tttccaaactc caatccagtt t

21

<210> 24

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 24

gaggagctga gtttccacta c

21

<210> 25

<211> 20

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:antisense

 <400> 25
 ggtaggggaag cctttgtgac 20

 <210> 26
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:peptide

 <400> 26
 hcysmtaagn gaagnaaarg hasasngnas gasnhh 36

 <210> 27
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA

 <400> 27
 gccacgcgtt tgtcagcaac aaagacagaa cag 33

 <210> 28
 <211> 31
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:antisense

 <400> 28
 gccacgcgtg ggaccatagg ggaaaaagta g 31

 <210> 29
 <211> 633

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 29

```

acaatgggtc ttgccagctc taccaccagc atccacacca tgcgtgctcct gctcctgatg 60
ctcttccacc tgggactcca agcttcaatc tcggcgcgcc aggactacaa ggacgacgat 120
gacaagacgc gtttgcagc aacaagaca gaacagatcc cagtcaacaa gacctatgct 180
gcttgccgcc aaaactggat tggagttgaa aataaatggt tttatttttc tgaataccca 240
agtaactgga cattcgcca ggcttctgc atggcacaag aggcccaact agctcggttt 300
gacaaccagg atgagctgaa tttcctaagt agatacaagg cgaattttga ttctgggatt 360
ggcctgcaca gagagtcgtc agagcaccct tggaaagtga cagacaacac tgagtataac 420
aacacgattc ccatcgggg agaggaaaga tttgcctacc tgaacaacaa cgggatcagc 480
agtaccagga tctattcact tcggatgtgg atctgtagca agctcaacag ctatagcctc 540
cactgccaaa ctctttttt tccttctag catttaccaa gagacgcttt tttagcctgtt 600
atctgtgggt gctacttttt ccctatggt ccc                                     633

```

<210> 30

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 30

```

gccacgcgtt cagtaaaaaa gacagccaag                                     30

```

<210> 31

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 31

```

gcccagcgta actacaggca ctgtgagg                                     28

```

<210> 32

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 32

ctcagtggtg tctgtccact tccaaggg

28

<210> 33

<211> 1628

<212> DNA

<213> Rattus rattus

<400> 33

cgccctact aaatgccac cagtgcacac ctacaggatc ctcccccaat cctctccagg 60
 acccttacac agaataagg acagacctcc ttgaggcaga gtagcagctg tggctgtctc 120
 gctgcctctg cctctgagtc attgtcaggt tccacagagt caagaattcc tcacaggacg 180
 taatcaatgc cgtccagtg acacctacag gatcctcccc cactcctctc caggaccttc 240
 acacagaatg aaggacagac ctccctgagg cagagtagca gctgtggctc gtctgtgccc 300
 tctgcctctg agtcattgtc aggttccaca gagtcaagaa ttccctcacg taaaatgtct 360
 caaggaaagc ttcccagaaa catccccctg gagtatctctg ctgggcttta ctgtgtctac 420
 gtatgtatca ttgtcctcag ttagctgtga gttgtctctt ctgtgtcttt gtcagtaaaa 480
 aagacagcac agatctcaac cataaatact tatgtctgct gcccgagaaa ctggtattga 540
 gttggaataa aatgttttta ttttaataaa ataccaagta actggacatt gagccagacc 600
 ctctgtaagg aacaaggggc cgagctagca cgatttgaca cggaggagga gctgaatttc 660
 ctaaggagat acaaagggag ttccaggttac tgggttcggtc tgcacagaga gtcacagc 720
 cacccttgga agtgagacaga caacactgag tataacaact cggtttccat cggaggagat 780
 gaaaacatg gcttctctgag tgacaatggg ttccagcagtg gcagggggta tatagtga 840
 aagtcgattt gtaggaagcc caacagctac acctcacagt gcctgtagtt ttgtgtctct 900
 ggttgagact ttgtcctaac agtcatgagg aacacagaa atggtatcta cagtgcctga 960
 atcatgaaca atctgctaaa atcatcttca attcataatg tgtggtgaca tctaagataa 1020
 caactgagcc atattttgct tgggagatca tgaattgttc tatattataa aggtattcag 1080
 gtatgagctg gttctcacat cttaaacata aactgaatca tgcagttatt agtatctctc 1140
 actttctttt ttctctcat taaattatat tattatttta tatccaaa accgtccctc 1200
 cctgtgtccc cctcttagag ttgttcaact catacccttc catctttact tctgaagaga 1260
 tgttccccca ccccaactct agtatctccc ttctcttgga cttaggact gtacaggatt 1320
 aggtgcaccc tctcatagtg aggccaaact tagggagctg gcagatgcgc tgccctaaaa 1380
 tgggtctggt ttccgcttcc caccctccca acagtgagcg ctccctgtag taaacaagtc 1440
 ctattattga tatgctgccc tggcctgcta ggttcagcat agtcacagcc tgtctgcatg 1500
 acccatgtgg cagcttgggg ttggttggtg ttggatacat aagctgatgt agggcattcc 1560
 cctggggtag tagatgattg tatcaagggt cctgaataaa ctgcttgaag aaaaaaaaaa 1620
 aaaaaaaaaa 1628

<210> 34

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 34

cagttttgcg ggcaagcagc atag

24

<210> 35

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 35

aggcagcccg caggaggtag aag

23

<210> 36

<211> 1206

<212> DNA

<213> Mus musculus

<400> 36

gtgcctctca gctttcaagt ttcaatcctg tagtggaaac tcagctcttc agctctgaga 60
 tgtgtgtcac aaagcgttcc ctacctatgc ttagtccac aggagcccg caggaggtag 120
 aagtgggtaa aattctccaa ggaagagc acggaacat ctccctgag tcttgtgcta 180
 agctttactg ctactatgga gtgatcatgg tctcactgt agctgtaatt gctctttctg 240
 ttgctttgtc agcaacaag acagaacaga tcccagtc aaagacctat gctgcttgcc 300
 cgcaaaactg gattggagtt gaaaaataat gtttttatt ttctgaatac ccaagtaact 360
 ggacattcgc ccagccttc tgcattggc aagaggccca actagctcgg ttgacaacc 420
 acagagagtc gtcagagcac ccttggaagt ggacagacaa cactgagtat aacaacaga 540
 ttccatccg gggagaggaa agatttgctt acctgaacaa caacgggatc agcagtacca 600
 ggatctatct acttcggatg tggatctgta gcaagctcaa cagctatagc ctccactgcc 660
 aaactccttt ttttccctcc tagcatttac caagagacgc tttttagcct gttatctgtg 720
 ggtgctactc tttccctat ggtcccaag tgctatcaaa ccagatagag aatatttctt 780
 aacatcagaa atgaaaacca tcatttcatt tcactgcagag atgtttcagt ggttaaaatc 840
 actgactact cttccgaagg tcttgagtc acatctgagc aaccacatgg tggctcaca 900
 acatccgtaa tgagatcttc tgaggtgtat gaaaacagct acactgtact ttactactctg 960
 caattttaaag catgagggag ataggagagt tagctacccc acactgatga gtcccaaaaa 1020
 ggacgaata acaggctaaa aagcctctct tgaactcttc atcctttctt ctccctcttg 1080
 gtcttttttaa agaccaggtc gctgaggaga aagagatgga gaaatggggg aagggaaggg 1140
 gagagggaca tgattggggg aggggagggg agggaaatta ataaaaaat aaaacaaaaa 1200
 tactac

1206

<210> 37

<211> 8622

<212> DNA

<213> *Mus musculus*

<400> 37

```

agatattgaa catgctccaa agatgattaa cttatgcagg tattctcttt ctctctctccc 60
cttccacttt ttctctcttc ttccctccct cctctctttt cttctctctc ctctctctcc 120
ctctctctct etccccctcc ctccccctcc ttctctctcc ttctctactc ctctctctct 180
ttctctcttt cttctctctt ttctctcttt cttctctctt ttctctcttt cttctctctt 240
tcctctcttc ctctctctct tcctctcttc ctctctctct ttctctcttc ttctctctct 300
tccttcagat ttatgtgtat gtgggtgcct tnagacagca gaggcaacac gtctcttgca 360
gctggagtta taggcagtta tgagctacac agtgtggttc ccaggaacag aaccaggggg 420
aatctcaatt gctgatctag gaagtcttag ttgtgaaaaa gtagtttcta ctcagaagtt 480
gaaaaagtcg taatatttta taaagaaata ctctatatt tgcatacgtt aaagagttga 540
cagcagctgg tgaggttaaca caatcacaaa agaactcaaa tgatatgtac tcactgataa 600
gtggatatta gccagaaaac ttaggatacc caagatataa gatacaattt gcaaaaacaca 660
tgaaactgaa gaagaaacgaa gaccaaagtg tggacacttt gccctctctt agaattggaa 720
acaatcatca atggaaggat tacagagaca aagtttgtag ctgagagaaa aggatggacc 780
atctagagac ttgccatatt cagggatcca tcccataatt agcctccaaa caatgacagc 840
attgcataca ctagcaagcg ttgtctgcaa ggaacctgat atagctgtct ctgtgagagc 900
tagggccggg ctagcaaac acataagtg atgctctcag tcagctattg gatgattac 960
agggccccc atggaggagc tagagaaagt atccaaggag ctaagagat ctgcaacctt 1020
gtagggtgcaa cattatgaac taaccagtc cccggagctc tgactctag ctgcataagt 1080
atcaaaagat ggctgtgtcg gccatcactg gaaagagagg cccattggac acgcaaaact 1140
tatatgccc agtacagggg aatgccaggg ccaaaaaaat ggggaatggg ggttaggaaa 1200
gtggggggca ggtgtgtggg gacttttggg ctagcattgg aaataataat gaggaaaata 1260
tgtataaaa aaagagttg acagctttct ttcaaaactt taaccaagac aaattaataa 1320
tgaagttaac gtgttatatt ttcaaggaa tggactcagg gcttaaaagc tcttgccaca 1380
taactctgac catctggcct ggatcacagg agaacagggc agcaggagag gacagactcc 1440
tacacatatg ctgtggcata gatatgcccc gctcaagaaa taaagtagtt ttttaattgg 1500
ccaaatgggt aactctccag tgtttcaaat agttgaatgt gactattgga tataaatatt 1560
tattacgcag taaaactctg ttggtttttt tgactctccc agggttctct gtttccaga 1620
actgttgtag ccctgtgata agaaagggtg agaggttcaa agctgttaaa aacaaatgat 1680
tcatagaatt cttagacaaa tggatggatc tggaggatgt catcttgagt aaggtaaccc 1740
aactcaggaa gaacacacat gatatgcact cactggtaag tggacattag ccagagaagt 1800
cagaatcctt tttagaaggg ggaacaaaat cccatggaa ggagttacag agacaaagt 1860
tggagcagag cctgaaggaa gagactgcca gagactgccc cacttgggga tccattccat 1920
aaacaaccac caaaccacac cactagcaga tgccaacaag agcctgctat agctgtctcc 1980
tgagggccct tgtcagtgcc tggcagatgc agaagtagat gctcacagtc attcaattga 2040
cagagcacaa agtccccaat gaagcagcta gagaaagtac ccaggaggct aaagggatct 2100
gcaaccctat aggtggaacc tcattatgaa ctaaccagta ccccgagct ctgtactcta 2160
ctgcataatg tatcaaaaga tggcctagtc ggccatcact gtaaaagagag gccattgga 2220
cttgcaaaat ttatatgccc cagtacagga gaacgccagg gccaaaagtg ggaatgggt 2280
gggcagggga ttgggggggg ggagggtatg ggggactttt ggaataacat tggaaatgta 2340
aattgaggaaa ataccataata aaaaatatta aaaaaaaaat aaaaagaaat cctgtgacc 2400
tcagtaaggt cagcttgaat tatgtttcta aatcagagtg tgctgaaaga gaaacgaaac 2460

```


acaaaagtaaa ccagaagcaa acaggaaggt cagttccag atggcgccag tgtggtctct 2520
 gaccttgaaa tgcgtttccc aatgagattt tgttagggcc tgagccaacc aagcgttgtt 2580
 gtatgtacag aaaggaggag ctaaaaggata aaataaatat tgaacctccc ccacgtattt 2640
 gtgcctctca gctttcaagt ttcaatcctg tagtggaac tcagctcctc agctctgaga 2700
 tgtgtgtcac aaaggcttcc ctacctatgc ttagtccac aggcagcccg caggaggtag 2760
 aagtgggtaa gtattcaata gtatttgaa caatgggagg ggcagagagg agtttcaaac 2820
 agggcaggaa ggcaaaagag ttgaaccttg aacaaaagat taagaacaga agggcgctct 2880
 taggccctgc actgtgggtc tgcagagcag gagaatgcag tcgggattag ctatgaggtt 2940
 gttacattag ttattctatt ggagcataca atactcgaat agttctcagg caagagaaat 3000
 gagcagcgag tcaccttcta actgccagag ctgtagccac agcgttctcg ctttgtactt 3060
 agcttgctag tccactcttc ccagggtatct ggtaagttac agtctgggtg atcatcataa 3120
 atgtcgttag taacagtttg ctttaagtcc ctgagtgag gaaactcaga caacagcttt 3180
 gcaatgtgca tagtggcaga agttgcctgg gaagcttgga gcttgtgttt tgcagatcca 3240
 tttgaattaa aatagaattg taaggggggt gcttgggtg ggttgggggt agggggcgct 3300
 gaacctactc aggaccaaat cctttctgtt ttgagctctt gataagttac agaaaaagaa 3360
 tataatgggg ttctctactt aattcttctg aaaggaaaga aaatttgttt tcttgtgttt 3420
 caaactgtct atgtctcatt atatttgttt cctttatttt ccttttcccc ctactcctg 3480
 ttttctcaca ttaatttttt ttttttaatt tgtgaaaaga ctactgaatt ttgagaaagt 3540
 aagattgaca tctatcaaaa tacaataatc caacaaaag ctactgttta tcaactaaac 3600
 caagtattct gaataataaa taataataat aataataata aattataata aattattatt 3660
 actgaggatg atgatgactg actgactgat tgacctgatt gattgattct ttggcaaaagt 3720
 ctacatactt accccaagct ggctgggaac tccgtctccc ctgcctcag cagggttgac 3780
 tttttaaatt caaatcacaa aatttttagc cattggaac atttcctgag aatgtggagc 3840
 tttctgtcca agtcagctg ttgcatagct agctcgagcg attttgaagc ctgtcttgtg 3900
 aatgtggagc tctgtctcca agtcgagctg ttgtataact agtcgagcg atgtacacac 3960
 ttcactcctt tgaagcagta gctgttttta tcaatgaaac agtttttaag taagctaaaa 4020
 accaggccag caatacttca tttcttggg ttttttgaga gatcattccc aacttactct 4080
 ttaaaataag acaggaaagt tatgttcaaa ttgtgctatg gaacacattc gaatttagaa 4140
 ggagatctgt gtgtatacag caaaattcct gtttacatat tagaaggaaa cagacagtat 4200
 cagaattata ctggtgtaaa cacagaggat tatctgtaaa tcttactctt aatatcatat 4260
 aagaaatgct ggtgtagaac tctaaataaa taaaatttacc atttcgtagt ttgaaatgc 4320
 ccaataacca taaatgtgct ccttttaattc caacttgcta agagtcttg ttattttaga 4380
 ctaataattt ttttttcaca tgattttggt aagctgttta aaatgctccc atatttttat 4440
 ccattagtta gtgcagtgtg ttctattaca tttatgtgcc tttattaatt tatttttaga 4500
 ctaggttctc tgagctgatg ccttacatag tccaggttga ttcacaaact ctactgtgac 4560
 caaggctagt ctgtactccc tgactccagc ttctgctccc ctgacactgg aaatataaaa 4620
 gtgtaccaac ctgtttgtct cgttgactgg agcaggagtt acacagggtg ttatgaggtg 4680
 ccccttgagc agctgagatt taggagctaa cctctgtccc ctagaagagc aacaattgat 4740
 ctttaactctc cagccatctc tgcagcctcc tgctgatccc agtctgtccc catcctggc 4800
 actcagtggtt attctcagtc ctagccagtc tattctttag gagcaaaatc tatgaatagc 4860
 ttggatgttg ttgtctttca gctgatctt cactcttctt gttcttgttt tctcaattgg 4920
 ccccttggtc aatgactgga agactccatg tttcccttcc atctagtctt ctgtgagcat 4980
 tagacatcat ttataaacca ggacctctg tgaaggggtt tgcaatgggt gaatacaagc 5040
 caaatctaca gataaattct tttctttaa ttgtttttga tgtggcgct tcaattttat 5100
 attttcaggt aaaattctcc aaggaaaaag gcacggaacc atctcccctg agtcttgtgc 5160
 taagctttac tgcatactat gagtatcat ggtcctcact gtactgttaa ttgctcttcc 5220
 tgtgtctttg tcaagtaagt gacttattct ccaaaattat tgacaacttt tccactttca 5280
 caaggctcag tatacttact gaccactgtg acccaggcat tgtgggaagg gctctggaga 5340

aatcacactg gaaattcctg ttctctggga acttaggttc tagctggaag gtgcagtga 5400
ggaacacaca gtctgtggtg tacacaggag tcttggttg gcactgtgta gaagatgaca 5460
ttcaataaagc tctcaactga gatgtcaggg acataaaatc ccttggggaa ctgttcaagg 5520
cagagaataa agagaggaaa ttccaagata ggaacctcaa aggtgaggac aggggaagagt 5580
aataatggcca ggaagatata gtgcctccca ccatgaccta gtttagttac caggctaatac 5640
tgaattttca aagtattaaa tggaaagtgt ctgaagttaag aaatttatag gatttttagtg 5700
ccacaatgtc agaatagtgc aatacaatct tgcactgtcc tcttaagtat ttgaagtcac 5760
cctttagtgc aatgtgtctg caccgtatat actacctaca caaaagtctc cacagcaatc 5820
tcaattatca ggctgggtgt cagtaggtgt cctcagagag tgcttgctgc tggagcaaatc 5880
cctactgtag tcaatggtca tccaaaagct cagaaaagta tatagaagtg atatagtgtt 5940
atagaagtg cactcctggg agccctactg acagttagca cctgagagag aatgggacac 6000
aggccacagc tgggaggcct ttagttaaa gcccactaga tcagtttaga aagctatcat 6060
cagallcaca cctcacagct gagctcagga ggggtgtgcca aaacgagaga agacctgctt 6120
gccatgatcc atgttattct ctacatttta gcaacaaga cagaacagat cccagtcaac 6180
aagacctatc ctgctgtccc gcaaaactgg attggagtgt aaaaataagt tttttattct 6240
tctgaatacc caagtaactg gacattcgcc caggccttct gcattggcca agaggcccaa 6300
ctagtctggt tgcacaacca ggtatgagctg gtaagcaatg ggcagggtat ggtttgtctg 6360
tctgttctgt tgaatattat attgccttga gatagagagt tacagatgag gctctaggaa 6420
ggtatccatc ccaagcacat ggagacatag ggaatgtgag tgtgtgccat ttgctgtatgc 6480
ttgacttctg actggagccc tgagacagtc aagaaacttt ctctcatgaa gtgttcacatg 6540
tcagtgtgaa ggtcagatat gccattttac tggatacctg gtgtgtcatca gtgttttccc 6600
atatgtctgc acttggttgt tacagaagga agcaactgtt aataactgca atgggaggtt 6660
aaccacagaac tgagttaatgt gaccctcagt tacacctcc tgttatctct agaggaatct 6720
gtggagtggg gagattccag gatcatctga aacaagagaa cacatgtatt ctgtgtcttt 6780
gtgtctgatg ccaagcattc ctaatgagat acaaggcgaa ttttgattcc tggatggcc 6840
tgacacagaga gtctgcagag cacccttggg agtggacaga caaactgag tataacaaca 6900
cgtatgtttt cacaagtttt ttctctctat tatgttcatg tgttgtgata tgtgtgagt 6960
gtggctatgg gagatgaaag gcagtgtcat gtgaagccaa ttgtactggg aaggaagaaa 7020
aaagaaaaatg aacccttgca tggaggtgtg gctcagaggt agagattgtg tttacatgca 7080
acagcccaatc ccagaaaaa tccacattcc cacaaactta aatgcttcag aggttttccc 7140
gtttattggc tgtcattttc aaaactttca cttagtgttg ttttaactca aatctttact 7200
ctaatgatgg tgtctgggag tagctattgt ttgctctggt tccaaactaa acattttctg 7260
tgttgataaa tgtctgtgta gggatataga cagagcctta gatgggcagt gggggctctg 7320
aaatcccaga aagccactgc agtatctgca aggctgagat tcagctttcc actatttgc 7380
tgtctgcacc tttctaggaa agcagagact ctaagtaaat ttggaacctc ctctaaagtc 7440
tcacatcacac tgagctccca aaacagttct tgggtttgag ctgttttccc gggatggtaa 7500
atcacagact cagtcacatc catcactgaa gcccttagag ccatttatta agaagtgggc 7560
gtcccatatc ataaaatgcc taataacaga attgaaaaac acccttagtc gggctactca 7620
tggtctcagt tcatttgaac atggcagcga gccacagccc aatgccttgt acacacatta 7680
caggattcac catggacaaa tgacaaaagg gtggtgtaca aatcctgaga atatgagaca 7740
gtagggttaa aactaatgca ggtgattccc caggagcttt ttgattcata ttaccacaaa 7800
tcagtggaga ctgggtgagat ttcaattgcag gagcaaatgc agttctgggt tctgcaggct 7860
tactgttttt ggtttctttt caggattccc atccggggag aggaagattt tgcctacctg 7920
acacaaacag ggaatcagca taccaggatc tattcactgc gtagtggtat ctgtgacaag 7980
ctcaacagct atagcctcca ctgccaaact ccttttttct ctctctagca tttaccaaga 8040
gacacttttt agcctgttat ctgtgggtgc tactctttcc cctatggctc caaagtgtca 8100
tgcaatcaga tagaataat ttcttaacat cagaaatgaa aaccatcatc tcaattcatg 8160
cagagattgt tcagtggtta aaatcactga ctactcttcc gaaggctcctg agttcacate 8220

```

tgagcaacca catggtggct cacaacatc cgtaatgaga tcttctgagg tgtatgaaaa 8280
cagctacact gtactttata ctctgcaatt taaagcatga gggacatagg agagttagct 8340
acccacacact gatgagtccc aaaaggagc aaataacagg ctaaaaagcc tctcttgaac 8400
tcttcactct ttcttctccc tcttgggtctt tttaaagacc aggtcgctga ggagaaagag 8460
atggagaagt gggggaaggg aaggggagag ggacatgatt gggggagggg aggggaagga 8520
aattaataaa aaaataaaac caaataacta catttgtacg gacttcattt atgcctattg 8580
ctgtatgggt tcgtatataa ttacccacc tgtgctcgag ca 8622

```

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 38

gtgggtgctc agatgtgaac

20

<210> 39

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 39

ttcacacatc ccagaagagg ac

22

<210> 40

<211> 137

<212> DNA

<213> Mus musculus

<400> 40

```

mcvtkasmst gsvvgkgrh gtsscakycy ygvmtvava svasatktvn ktyaacnwg 60
nkcyssnwt aacmaardn dnmrykands wghrshlkw tdntynntng raynnngsst 120
rysimwcskn syshets 137

```

<210> 41

<211> 147

<212> DNA

<213> Mus musculus

<400> 41
 mdctgkvhnmd nacvkgnggt gdrkrssrass sakycygyvm vtvavvasva svtktnktya 60
 acknwgvgnk cysytsnwta tcmaraardnk nmrykandsw ghrsshkwkt dntynnmvgv 120
 caysngngsss rhyrwcsknn yshctvv 147

<210> 42
 <211> 149
 <212> DNA
 <213> Mus musculus

<400> 42
 mdctgkvhnmd nacvkgnggt ggkvgkcrst vsvkyccygv mvtvavasva stktknktya 60
 acsknwtgvg nkcygyrwn taacmaaraard nkrkgddcwg hrsshkwkwn ntynnmvgv 120
 ryayssdrss srswynrmwcs knnynhctv 149

<210> 43
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:antisense

<400> 43
 ctctgctcag cccaatccag tgatcag 27

<210> 44
 <211> 820
 <212> DNA
 <213> Homo sapiens

<400> 44
 gcagttattt gtctgtattt aattgtttaa atgtttttca ataatttttt ccaggttgtc 60
 tgcattcaaa agagcattct attaaagcta ccttaatttg gcgcttattt ttcttaataca 120
 tgtttctgac aatcatagtg tgtggaaatg ttgctgtctt aagcgcaata agagctaaat 180
 gccatcaaga gccatcagta tgtcttcaag ctgcatgcc cagaagcttg attggttttc 240
 aaagaaagtg ttcttatttt tctgatgaca ccaagaactg gacatcaagt cagagggtttt 300
 gtgactcaca agatgctgat ctgtctcagg ttgaaagctt ccagggaactg aatttctctg 360
 tgagatataa aggcccatct gatcactgga ttgggctgag cagagacaaa ggccaacctat 420
 ggaaatggat aatagggtact gaatggacaa gacagtttcc tatctctgga gcaggagagt 480
 gtgcctattt gaatgacaaa ggtgccagta gtgccaggca ctacacaaaagg aggaagtgga 540
 ttgtgtccaa atcagatata catgtctaga tgttacagca aagccccaac taatctttag 600
 aagcatattg gaactgataa ctccatttta aaatgagcaa agaatttatt tcttatacca 660
 acaggtatat gaaaatatgc tcaatatcac taataactgg gaaaatacaa atcaaaatca 720

tagtaaaata ttacctgttt tcatgggtgct aatattacct gttctccac tgctaataac 780
 abaccgcgaga ctgagtaatt tataaataaa gagatttaac 820

<210> 45

<211> 845

<212> DNA

<213> Homo sapiens

<400> 45

atagaaactg gaggcaaaat gcatgacagt aacaatgtgg agaagacat tacaccatct 60
 gaattgccctg caaaccagg ttgtctgcat tcaaaagagc attctattaa agctacctta 120
 atttggcgct tatTTTTtett aatcatgttt ctgacaatca tagtggtgtgg aatggtgtgct 180
 gctttaagcg caataagagc taactgccat caagagccat cagtatgtct tcaagctgca 240
 tgcccagaaa gctggattgg ttttcaaaga aagtgtttct atttttctga tgacaccaag 300
 aactggacat caagtgcagag gttttgtgac tcacaagatg ctgatcttgc tcaggttgaa 360
 agcttccagg aactgaattt cctgttgaga tataaaggcc catctgatca ctggattggg 420
 ctgagcagag acaagggcca accatggaaa tggataaatg gtactgaatg gacaagacag 480
 tttctatcc tgggagcagg agagtgtgcc tatttgaatg acaagggtgc cagtagtgcc 540
 aggcactaca caaaggaggaa gtggatttgt tccaaatcag atatacatgt ctgatgttta 600
 cagcaaaagcc ccaactaatc tttagaagca tattggaact gataactcca ttttaaaatg 660
 agcaaaagaa ttatttctta taccacacag tatatgaaaa tatgctcaat atcactaata 720
 actgggaaaa tcaaatcaa aatcatagta aaatattacc tgttttcatg gtgctaatac 780
 tactgtttct cccactgcta atgacatacc cgagactgag taattataaa ataaagagat 840
 ttaac 845

<210> 46

<211> 937

<212> DNA

<213> Homo sapiens

<400> 46

gatggaatta ctagaaggct ttatcatagc tcttaggaca aactagaaat gatgaaatag 60
 taaagaaaaa gatataataa atettacaga aactggaact cagtctaat gcaactctat 120
 ttctatttga taaaggcaat agctgtccaa cctggaactt atttcttaca ggttgtgtgc 180
 attcaaaaa gcaattctatt aaagctacct taatttggcg ctatttttct ttaatcatgt 240
 ttctgacaa catagtgtgt ggaatggttg ctgctttaag tgcaataaga gctaactgcc 300
 atcaagagcc atcagtatgt cttcaagctg catgccacga aagctggatt ggttttcaaa 360
 gaaagtgttt ctatttttct gatgacacca agaactggac atcaagtgcag aggttttgtg 420
 actcacaaga tgctgatctt gctcaggttg aaagcttcca ggaactaaat ttctgttgga 480
 gatataaagg ccatctgat cactggattg ggctgagcag agaacaaggc caaccatgga 540
 aatggataaa tggtagtgaa tggacaagac agtttctctat cctgggagca ggagagtgtg 600
 cctatttgaa tgacaaaagt gccagtatgt ccaggcacta cacaagagg aagtggattt 660
 gttccaaatc agatatacat gtctagatgt tacagcaaa ccccaactaa tctttagaag 720
 catatttgaa ctgataaact catTTTtaaa tgagcaaaaga atttatttct tataccaaca 780
 ggtatatgaa aatatgtctca atatcactaa taactggaaa aatacaaatc aaatcatag 840
 taaaatatta cctgttttca tgggtctaat attacctgtt ctcccactgc taatgacata 900

cccgcgactg agtaatttat aaataaagag atttaat

937

<210> 47

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 47

gctgatcttg ctcaggttga aagcttcc

28

<210> 48

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 48

Cys Val Thr Lys Ala Ser Leu Pro Met Leu Ser Pro Thr Gly Ser Pro

1

5

10

15

Gln Glu

<210> 49

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 49

Cys Val Gln Lys Pro Glu Glu Gly Asn Gly Pro Leu Gly Thr Gly Asp

1

5

10

15

<210> 50

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 50

tcagaattca cctatgctgc ttgccgcg

28

<210> 51

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 51

ggttaagctt caggctaaaa agcgtctctt gg

32

<210> 52

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 52

tcagaattca cctatgctgc ttgcccgaa

29

<210> 53

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 53

ggttaagctt gggaccatag gggaaaaaagt ag

32

<210> 54

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 54

tcagaattca cctatgctgc ttgctcaaa

29

<210> 55

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA

<400> 55

gcggaattcc ttcaagctgc atgccc

26

<210> 56

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:antisense

<400> 56

cctgggatcc gctttgctgt aacatctaga c

31

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00864

| | | | | | | | | | | | | | | | | | | |
|---|---|--|--|--|-----|---|-----|---|-----|--|-----|--|-----|--|-----|--|-----|---|
| A. CLASSIFICATION OF SUBJECT MATTER | | | | | | | | | | | | | | | | | | |
| Int. Cl. ⁷ : C12N 15/12, 15/11; C12Q 1/68; C07K 14/475, 16/18; A61K 38/18, G01N 33/68. | | | | | | | | | | | | | | | | | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | | | | | | | | | | | | | | | | | |
| B. FIELDS SEARCHED | | | | | | | | | | | | | | | | | | |
| Minimum documentation searched (classification system followed by classification symbols) WORLD PATENT INDEX (WPAT) AND CHEMICAL ABSTRACTS (CA) KEYWORDS (KW) - SEE ELECTRONIC DATABASE BOX BELOW. | | | | | | | | | | | | | | | | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Medline (ML) Kw Genbank, Genpept, EMBL, PIR and Dgene (Derwent)- sequences (See Electronic Database Box Below). | | | | | | | | | | | | | | | | | | |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPAT, CA, ML: KW "osteoclast? inhibit?"; "osteoprotegerin and osteoblast"; Genbank, Genpept, EMBL, Dgene: Sequences as defined in the claims (eg seq id nos. 2, 4, 7-16, 18-56). | | | | | | | | | | | | | | | | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | | | | | | | | | | | | | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | | | | | | | | | | | | | | | | |
| X | Genbank accession no. AF121352 (published 15 June 1999) - | 1-13, 32, 33 and 35. SEQ ID NOS: 2-17, 19, 22-24, 28, 29, 32, 33, 36-39 and 54. | | | | | | | | | | | | | | | | |
| P, X | Genbank accession no. AF192526 (published 1 November 1999) - | 1-4, 32, 33 and 35. SEQ ID NOS: 13 and 15. | | | | | | | | | | | | | | | | |
| P, X | Genbank accession no. AF133299 (published 1 January 2000) - | 1-4, 32, 33 and 35. SEQ ID NOS: 43-47, 55 and 56. | | | | | | | | | | | | | | | | |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex | | | | | | | | | | | | | | | | | | |
| * Special categories of cited documents: <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> </table> | | | "A" | document defining the general state of the art which is not considered to be of particular relevance | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | "E" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | "L" | document referring to an oral disclosure, use, exhibition or other means | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | "O" | document published prior to the international filing date but later than the priority date claimed | "&" | document member of the same patent family |
| "A" | document defining the general state of the art which is not considered to be of particular relevance | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | | | | | | | | | | | | | | | |
| "E" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | | | | | | | | | | | | | | | |
| "L" | document referring to an oral disclosure, use, exhibition or other means | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | | | | | | | | | | | | | | | |
| "O" | document published prior to the international filing date but later than the priority date claimed | "&" | document member of the same patent family | | | | | | | | | | | | | | | |
| Date of the actual completion of the international search 6 September 2000 | | Date of mailing of the international search report 15 SEP 2000 | | | | | | | | | | | | | | | | |
| Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustria.gov.au Facsimile No. (02) 6285 3929 | | Authorized officer J H CHAN Telephone No : (02) 6283 2340 | | | | | | | | | | | | | | | | |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00864

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|---|--|------------------------------|
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | Genpept accession no. AAD22055 (published 15 June 1999) | 14-18. SEQ ID NOS: 49. |
| X | WO 9828423 A (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 2 July 1998. See pages 10-16 and the examples. ✓ | 1-3. |
| X | AU 702557 (46773/96) B (SNOW BRAND MILK PRODUCTS CO. LTD.) 11 September 1996. See pages 3-11 and the examples.. | 1-3. |
| X | AU 718458 (38661/97) B (SNOW BRAND MILK PRODUCTS CO. LTD.) 11 May 1998. See pages 6-7 and the examples. ✓ | 1-3. |
| A | WO 97/23614 A (AMGEN INC.) 3 July 1997. . | |
| A | Endocrine Review 20 no. 3 pages 345-357 (1999) Suda T. <i>et al</i> "Modulation of osteoclast differentiation and function by the new members of the Tumor Necrosis Factor Receptor and ligands families". | |
| A | Life Sciences volume 65 no 11 pages 1087-1102 (1999) Greenfield E M <i>et al</i> "Minireview: Regulation of osteoclast activity". | |

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00864

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent Document Cited in Search Report | | | Patent Family Member | | | | |
|--|---------|----|----------------------|----|----------|----|----------|
| WO | 9828423 | AU | 59015/98 | EP | 951546 | US | 5985832 |
| AU | 702557 | WO | 9626217 | EP | 816380 | FI | 973402 |
| | | NO | 973801 | CA | 2213469 | CN | 1175956 |
| | | HU | 9900422 | | | | |
| AU | 718458 | WO | 9807840 | EP | 874045 | FI | 980853 |
| | | NO | 981748 | NZ | 330400 | CA | 2235148 |
| | | CN | 1198776 | JP | 10057071 | ZA | 9707402 |
| WO | 9723614 | AU | 14686/97 | BG | 101813 | CA | 2210467 |
| | | CN | 1182452 | CZ | 9702538 | DE | 19654610 |
| | | EP | 784093 | EP | 870023 | FR | 2742767 |
| | | GB | 2312899 | HU | 9801122 | NO | 973699 |
| | | NZ | 326579 | PL | 321938 | SK | 1107/97 |
| | | TR | 970550 | US | 6015938 | | |
| END OF ANNEX | | | | | | | |